TITLE OF THE INVENTION

PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE

COMPOUNDS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application Serial No.

61/861 ,291 , filed August 1 , 2013, and U.S. Provisional Application Serial No. 61/863,1 18, filed August 7, 2013, each of which is incorporated herein by reference in its entirety.

SEQUENCE LISTING

[0002] Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: one xxx Bytes ASCII (Text) file named "filename.txt," created on July 22, 2014.

FIELD OF INVENTION

[0003] In some aspects, the present invention relates to pharmaceutical compositions and methods of using the same to treat leukemia. More particularly, the present invention relates to compositions comprising dispersions of thienotriazolodiazepine compounds which have improved solubility and bioavailability and methods for treating a BCR-ABL positive acute lymphoblastic leukemia and/or a CD34 positive acute myeloid leukemia.

BACKGROUND OF THE INVENTION

[0004] The compound of Formula (1), described herein below, has been shown to inhibit the binding of acetylated histone H4 to the tandem bromodomain (BRD)-containing family of transcriptional regulators known as the BET (bromodomains and extraterminal) proteins, which include BRD2, BRD3, and BRD4. See U.S. Patent Application Publication No. 2010/0286127 Al , which is incorporated herein by reference in its entirety. The BET proteins have emerged as major epigenetic regulators of proliferation and differentiation and also have been associated with predisposition to dyslipidemia or improper regulation of adipogenesis, elevated inflammatory profile and risk for cardiovascular disease and type 2 diabetes, and increased susceptibility to autoimmine diseases such as rheumatoid arthritis and systemic lupus erythematosus as reported by Denis, G.V. "Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation," Discov Med 2010; 10:489-499, which is incorporated herein by reference in its entirety. Accordingly, the compound of formula (II) may be useful for treatment of various cancers, cardiovascular disease, type 2 diabetes, and autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus.

[0005] The thienotriazolodiazepine compound of Formula (1), described herein below, presents highly specific difficulties in relation to administration generally and the preparation of galenic compositions in particular, including the particular problems of drug bioavailability and variability in inter- and intra-patient dose response, necessitating development of a non-conventional dosage form with respect to the practically water-insoluble properties of the thienotriazolodiazepine.

[0006] Previously, it had been found that thienotriazolodiazepine compound of Formula (1) could be formulated with the carrier ethyl acrylate-methyl methacrylate-trimethylammonioethyl methacrylate chloride copolymer (Eudragit RS, manufactured by Rohm) to provide an oral formulation that preferentially released the pharmaceutical ingredient in the lower intestine for treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease as reported in U.S. Patent Application Publication No. 20090012064 Al , which is incorporated herein by reference in its entirety. Through various experiments including animal tests, it was found that that for inflammatory bowel diseases, the thienotriazolodiazepine compound of Formula (1) release in a lesion and a direct action thereof on the inflammatory lesion were more important than the absorption of thienotriazolodiazepine compound of Formula (1) into circulation from the gastrointestinal tract. However, for many other disease conditions high absorption of

thienotriazolodiazepine compound of Formula (1) into the circulation from gastrointestinal tract is required. Accordingly, a need exists for formulations of thienotriazolodiazepine compound of Formula (1) that can provide high absorption of thienotriazolodiazepine compound of Formula (1) into the circulation from gastrointestinal tract.

BRIEF SUMMARY OF THE INVENTION [0007] In one embodiment, the present invention provides for a method of treating an acute lymphoblastic leukemia comprising administering to a patient a pharmaceutically acceptable amount of a composition comprising a thienotriazolodiazepine compound, said thienotriazolodiazepine compound being represented by the following Formula (1):

wherein Ri is alkyl having a carbon number of 1 -4, R ₂ is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydro xyl group, R ₃ is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1- 4, alkoxy having a carbon number of 1 -4 or cyano; ~ R ₅ ~(CH ₂ ) _m ~R6 wherein R5 is a hydrogen atom or alkyl having a carbon number of 1 -4, m is an integer of 0-4, and R ₆ is phenyl or pyridyl optionally substituted by a halogen atom; or— NR7--CO— (CH ₂ ) _n — Rs wherein R ₇ is a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and Rs is phenyl or pyridyl optionally substituted by a halogen atom, and R4 is --(CH ₂ ) _a — CO--NH--R9 wherein a is an integer of 1-4, and R9 is alkyl having a carbon number of 1 -4; hydro xyalkyl having a carbon number of 1 -4; alkoxy having a carbon number of 1-4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1 -4, alkoxy having a carbon number of 1 -4, amino or a hydroxyl group or ~(CH ₂ )b~ COOR10 wherein b is an integer of 1 -4, and Rio is alkyl having a carbon number of 1 -4, or a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof , wherein the

thienotriazolodiazepine compound is formed as a solid dispersion comprising an amorphous thienotriazolodiazepine compound wherein the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1) and a pharmaceutically acceptable polymer. In one such embodiment, the pharmaceutically acceptable polymer is hydroxypropylmethylcellulose acetate succinate having a thienotriazolodiazepine compound to hydroxypropylmethylcellulose acetate succinate (HPMCAS), weight ratio of 1 :3 to 1 : 1.

[0008] In one embodiment, the thienotriazolodiazepine compound represented by Formula 1 is independently selected from the group consisting of: (i) (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl- 6H-thieno[3,2-fJ[l,2,4]triazolo- [4,3-a][l,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof, (ii) methyl (S)-{4-(3'-cyanobiphenyl-4-yl)-2,3,9-trimethyl-6H-thieno[3,2 - fJ[ l ,2,4]tri-azolo[4,3-a][l ,4]diazepin-6-yl}acetate, (iii) methyl (S)- {2,3,9-trimethyl-4-(4- phenylaminophenyl)-6H-thieno[3,2-fJ [l ,2,4]triaz-olo[4,3-a][l ,4]diazepin-6-yl}acetate; and (iv) methyl (S)- { 2 ,3 ,9 -trimethyl-4- [4-(3 -phenylpropionylamino)phenyl]-6H-thieno [3 ,2-f- ] [ 1 ,2 ,4]triazolo [4,3-a] [ 1 ,4]diazepin-6-yl} acetate.

[0009] In another embodiment, the thienotriazolodiazepine compound is (5 -2-(4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- J[l ,2,4]triazolo[4,3- ][l ,4]diazepin-6-yl)-N-(4- hydroxyphenyl)acetamide dihydrate.

[0010] In still yet another embodiment, the solid dispersion exhibits a single glass transition temperature (Tg) inflection point ranging from about 130 °C to about 140 °C.

[0011] The present disclosure further provides for an embodiment providing for a method of treating an acute myeloid leukemia comprising the step of administering to a patient a

pharmaceutically acceptable amount of a composition comprising a thienotriazolodiazepine compound, said thienotriazolodiazepine compound being represented by the following Formula (1)

wherein Ri is alkyl having a carbon number of 1 -4, R ₂ is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1 -4 optionally substituted by a halogen atom or a hydro xyl group, R ₃ is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1 - 4, alkoxy having a carbon number of 1 -4 or cyano; ~NR5~(CH ₂ )m~R6 wherein R5 is a hydrogen atom or alkyl having a carbon number of 1 -4, m is an integer of 0-4, and R ₆ is phenyl or pyridyl optionally substituted by a halogen atom; or— NR7--CO— (CH ₂ ) _n — Rs wherein R ₇ is a hydrogen atom or alkyl having a carbon number of 1 -4, n is an integer of 0-2, and Rs is phenyl or pyridyl optionally substituted by a halogen atom, and R4 is --(CH ₂ ) _a — CO--NH--R ₉ wherein a is an integer of 1 -4, and R ₉ is alkyl having a carbon number of 1 -4; hydro xyalkyl having a carbon number of 1 -4; alkoxy having a carbon number of 1 -4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1 -4, alkoxy having a carbon number of 1 -4, amino or a hydroxyl group or ~(CH ₂ ) _b ~ COORio wherein b is an integer of 1 -4, and Rio is alkyl having a carbon number of 1 -4, or a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof, wherein the

thienotriazolodiazepine compound is formed as a solid dispersion comprising an amorphous thienotriazolodiazepine compound wherein the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1) and a pharmaceutically acceptable polymer.. In one such embodiment, the pharmaceutically acceptable polymer is hydroxypropylmethylcellulose acetate succinate having a thienotriazolodiazepine compound to hydroxypropylmethylcellulose acetate succinate (HPMCAS), weight ratio of 1 :3 to 1 : 1.

[0012] In one embodiment, the thienotriazolodiazepine compound represented by Formula 1 is independently selected from the group consisting of: (i) (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl- 6H-thieno[3,2-fJ[ l ,2,4]triazolo- [4,3-a][l ,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof, (ii) methyl (S)-{4-(3'-cyanobiphenyl-4-yl)-2,3,9-trimethyl-6H-thieno[3,2 - fJ[ l ,2,4]tri-azolo[4,3-a][l ,4]diazepin-6-yl}acetate, (iii) methyl (S)- {2,3,9-trimethyl-4-(4- phenylaminophenyl)-6H-thieno[3,2-fJ [l ,2,4]triaz-olo[4,3-a][l ,4]diazepin-6-yl}acetate; and (iv) methyl (S)- { 2 ,3 ,9 -trimethyl-4- [4-(3 -phenylpropionylamino)phenyl]-6H-thieno [3 ,2-f- ] [ 1 ,2 ,4]triazolo [4,3-a] [ 1 ,4]diazepin-6-yl} acetate.

[0013] In another embodiment, the thienotriazolodiazepine compound is (5 -2-(4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- J[l ,2,4]triazolo[4,3- ][l ,4]diazepin-6-yl)-N-(4- hydroxyphenyl)acetamide dihydrate.

[0014] In one embodiment, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1). In still yet another embodiment, the solid dispersion exhibits a single glass transition temperature (Tg) inflection point ranging from about 130 °C to about 140 °C.

[0015] In one aspect, the present invention provides a method of treating a BCR-ABL positive acute lymphoblastic leukemia comprises the step of administering to a patient a pharmaceutically acceptable amount of a composition comprising a thienotriazolodiazepine compound. In some preferred embodiments of the method of treating a BCR-ABL positive acute lymphoblastic leukemia, the thienotriazolodiazepine compound is represented by the structure of Formula (1):

wherein Ri is alkyl having a carbon number of 1 -4; R ₂ is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydro xyl group; R ₃ is a halogen atom; a phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano; --NR5— (CH ₂ ) _m --R6 wherein R5 is a hydrogen atom or alkyl having a carbon number of 1 -4, m is an integer of 0-4, and R ₆ is phenyl or pyridyl optionally substituted by a halogen atom; or --NR ₇ --CO--(CH ₂ ) _n --R8 wherein R ₇ is a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and Rs is phenyl or pyridyl optionally substituted by a halogen atom, and R4 is --(CH ₂ ) _a — CO--NH--R ₉ wherein a is an integer of 1-4, and R ₉ is alkyl having a carbon number of 1-4; hydro xyalkyl having a carbon number of 1-4; alkoxy having a carbon number of 1-4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1 -4, alkoxy having a carbon number of 1 -4, amino or a hydroxyl group or ~(CH ₂ )b~ COOR ₁₀ wherein b is an integer of 1 -4, and Rio is alkyl having a carbon number of 1 -4, or a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof.

[0016] In some preferred embodiments of the method of treating a BCR-ABL positive acute lymphoblastic leukemia, the thienotriazolodiazepine compound represented by Formula 1 is independently selected from the group consisting of:

(i) (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-fJ[l ,2,4]triazolo- [4,3- a][l,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof,

(ii) methyl (S)-{4-(3'-cyanobiphenyl-4-yl)-2,3,9-trimethyl-6H-thieno[3,2 -fJ [l ,2,4]tri- azolo[4,3-a][l ,4]diazepin-6-yl} acetate,

(iii) methyl (S)-{2,3,9-trimethyl-4-(4-phenylaminophenyl)-6H-thieno[3,2-f J[l ,2,4]triaz- olo[4,3-a][l ,4]diazepin-6-yl} acetate; and

(iv) methyl (S)- {2,3,9-trimethyl-4-[4-(3-phenylpropionylamino)phenyl]-6H-thi eno[3,2-f- ] [ 1 ,2 ,4]triazolo [4,3-a] [ 1 ,4]diazepin-6-yl} acetate. [0017] In some preferred embodiments of the method of treating a BCR-ABL positive acute lymphoblastic leukemia, the thienotnazolodiazepine compound represented by Formula 1 is (5 -2- (4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- J[l ,2,4]triazolo[4,3- ][l ,4]diazepin-6-yl)-N-(4- hydroxyphenyl)acetamide dihydrate.

[0018] In some preferred embodiments of the method of treating a BCR-ABL positive acute lymphoblastic leukemia, the thienotnazolodiazepine compound represented by Formula 1 is formed as a solid dispersion comprising an amorphous thienotnazolodiazepine compound of the Formula (1) and a pharmaceutically acceptable salt thereof or a hydrate thereof; and a pharmaceutically acceptable polymer.

[0019] In some preferred embodiments of the method of treating a BCR-ABL positive acute lymphoblastic leukemia, the thienotriazolodiazepine compound represented by Formula 1 is formed as a solid dispersion comprising an amorphous thienotriazolodiazepine compound of the Formula (1) and a pharmaceutically acceptable salt thereof or a hydrate thereof; and a pharmaceutically acceptable polymer, wherein the pharmaceutically acceptable polymer is

hydroxypropylmethylcellulose acetate succinate having a thienotriazolodiazepine compound to hydroxypropylmethylcellulose acetate succinate (HPMCAS), weight ratio of 1 :3 to 1 : 1.

[0020] In some preferred embodiments of the method of treating a BCR-ABL positive acute lymphoblastic leukemia, the solid dispersion comprising the thienotriazolodiazepine compound represented by Formula 1 , exhibits a single glass transition temperature ( g) inflection point ranging from about 130 °C to about 140 °C. In one embodiment, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1).

[0021] In another aspect, the present invention provides a method of treating a CD34 positive acute myeloid leukemia. In some exemplary embodiments of the method of treating a CD34 positive acute myeloid leukemia, the method comprises administering to a patient a

pharmaceutically acceptable amount of a composition comprising a thienotriazolodiazepine compound. In some preferred embodiments of the method of treating a CD34 positive acute myeloid leukemia, the method comprises administering to a patient a pharmaceutically acceptable amount of a composition comprising a thienotriazolodiazepine compound having the structure of Formula (1):

wherein Ri is alkyl having a carbon number of 1 -4, R ₂ is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydro xyl group, R ₃ is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1- 4, alkoxy having a carbon number of 1 -4 or cyano; ~ R ₅ ~(CH ₂ ) _m ~R6 wherein R5 is a hydrogen atom or alkyl having a carbon number of 1 -4, m is an integer of 0-4, and R ₆ is phenyl or pyridyl optionally substituted by a halogen atom; or— NR7--CO— (CH ₂ ) _n — Rs wherein R ₇ is a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and Rs is phenyl or pyridyl optionally substituted by a halogen atom, and R4 is --(CH ₂ ) _a — CO--NH--R9 wherein a is an integer of 1-4, and R9 is alkyl having a carbon number of 1-4; hydro xyalkyl having a carbon number of 1-4; alkoxy having a carbon number of 1-4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1 -4, alkoxy having a carbon number of 1 -4, amino or a hydroxyl group or ~(CH ₂ )b~ COOR ₁ 0 wherein b is an integer of 1 -4, and Rio is alkyl having a carbon number of 1 -4, or a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof.

[0022] In some preferred embodiments of the method of treating a CD34 positive acute myeloid leukemia, the thienotriazolodiazepine compound represented by Formula 1 is independently selected from the group consisting of:

(i) (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-fJ[l ,2,4]triazolo-[4,3- a][l,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof,

(ii) methyl (S)-{4-(3'-cyanobiphenyl-4-yl)-2,3,9-trimethyl-6H-thieno[3,2 -fJ[l ,2,4]tri- azolo[4,3-a][l ,4]diazepin-6-yl} acetate,

(iii) methyl (S)-{2,3,9-trimethyl-4-(4-phenylaminophenyl)-6H-thieno[3,2-f J[l ,2,4]triaz- olo[4,3-a][l ,4]diazepin-6-yl} acetate; and

(iv) methyl (S)- {2,3,9-trimethyl-4-[4-(3-phenylpropionylamino)phenyl]-6H-thi eno[3,2-f- ] [ 1 ,2 ,4]triazolo [4,3-a] [ 1 ,4]diazepin-6-yl} acetate. [0023] In some preferred embodiments of the method of treating a CD34 positive acute myeloid leukemia, the thienotriazolodiazepme compound represented by Formula 1 is (5')-2-(4-(4- chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- J[l ,2,4]triazolo[4,3- ][l ,4]diazepin-6-yl)-N-(4- hydroxyphenyl)acetamide dihydrate.

[0024] In some preferred embodiments of the method of treating a CD34 positive acute myeloid leukemia, the thienotriazolodiazepme compound represented by Formula 1 is formed as a solid dispersion comprising an amorphous thienotriazolodiazepme compound of the Formula (1) and a pharmaceutically acceptable salt thereof or a hydrate thereof; and a pharmaceutically acceptable polymer. In one embodiment, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1).

[0025] In some preferred embodiments, the method of treating a CD34 positive acute myeloid leukemia comprises administering to a patient a pharmaceutically acceptable amount of an amorphous thienotriazolodiazepine compound of the Formula (1) and a pharmaceutically acceptable salt thereof or a hydrate thereof, wherein thienotriazolodiazepine compound of the Formula ( 1 ) is formed as a solid dispersion comprising an amorphous thienotriazolodiazepine compound of the Formula (1) and a pharmaceutically acceptable salt thereof or a hydrate thereof; and a

pharmaceutically acceptable polymer, and wherein the pharmaceutically acceptable polymer is hydroxypropylmethylcellulose acetate succinate having a thienotriazolodiazepine compound to hydroxypropylmethylcellulose acetate succinate (HPMCAS), weight ratio of 1 :3 to 1 : 1.

[0026] In some preferred embodiments, the method of treating a CD34 positive acute myeloid leukemia comprises administering to a patient a pharmaceutically acceptable amount of an amorphous thienotriazolodiazepine compound of the Formula (1) and a pharmaceutically acceptable salt thereof or a hydrate thereof formed in a solid dispersion in a pharmaceutically acceptable polymer, wherein the solid dispersion exhibits a single glass transition temperature (Tg) inflection point ranging from about 130 °C to about 140 °C. In one embodiment, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1).

BRIEF DESCRIPTION OF THE DRAWINGS [0027] The foregoing summary, as well as the following detailed description of embodiments of the pharmaceutical compositions including thienotriazolodiazepine formulations and methods of the present invention, will be better understood when read in conjunction with the appended drawings of exemplary embodiments. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities shown.

[0028] In the drawings:

[0029] Figure 1 A illustrates dissolution profile of a comparator formulation comprising a solid dispersion comprising 25% compound (1 -1) and Eudragit LI 00-55.

[0030] Figure IB illustrates dissolution profile of a comparator formulation comprising a solid dispersion comprising 50% compound (1 -1) and Eudragit LI 00-55.

[0031] Figure 1C illustrates dissolution profile of an exemplary formulation comprising a solid dispersion comprising 25% compound (1 -1) and polyvinylpyrrolidone (PVP).

[0032] Figure ID illustrates dissolution profile of an exemplary formulation comprising a solid dispersion comprising 50% compound (1 -1) and PVP.

[0033] Figure IE illustrates dissolution profile of an exemplary formulation comprising a solid dispersion comprising 25% compound (1 -1 ) and PVP -vinyl acetate (PVP-VA).

[0034] Figure IF illustrates dissolution profile of an exemplary formulation comprising a solid dispersion comprising 50% compound (1 -1) and PVP-VA.

[0035] Figure 1G illustrates dissolution profile of an exemplary formulation comprising a solid dispersion comprising 25% compound (1 -1) and hypromellose acetate succinate (HPMCAS-M).

[0036] Figure 1H illustrates dissolution profile of an exemplary formulation comprising a solid dispersion comprising 50% compound (1 -1) and HPMCAS-M.

[0037] Figure 11 illustrates dissolution profile of an exemplary formulation comprising a solid dispersion comprising 25% compound (1 -1) and hypromellose phthalate (HPMCP-HP55).

[0038] Figure 1 J illustrates dissolution profile of an exemplary formulation comprising a solid dispersion comprising 50% compound (1 -1) and HMCP-HP55.

[0039] Figure 2A illustrates results of in vivo screening of an exemplary formulation comprising a solid dispersion of 25% compound (1 -1) and PVP.

[0040] Figure 2B illustrates results of an in vivo screening of an exemplary formulation comprising a solid dispersion of 25% compound (1-1 ) and HPMCAS-M.

[0041] Figure 2C illustrates results of an in vivo screening of an exemplary formulation comprising a solid dispersion of 50% compound (1-1 ) and HPMCAS-M.

[0042] Figure 3 illustrates powder X-ray diffraction profiles of solid dispersions of compound (1 -1). [0043] Figure 4A illustrates modified differential scanning calorimetry trace for a solid dispersion of 25% compound (1 -1) and PVP equilibrated under ambient conditions.

[0044] Figure 4B illustrates modified differential scanning calorimetry trace for a solid dispersion of 25% compound (1 -1) and HPMCAS-M equilibrated under ambient conditions.

[0045] Figure 4C illustrates modified differential scanning calorimetry trace for a solid dispersion of 50% compound (1 -1) and HPMCAS-M equilibrated under ambient conditions.

[0046] Figure 5 illustrates plot of glass transition temperature (Tg) versus relative humidity (RH) for solid dispersions of 25% compound (1 -1 ) and PVP or HMPCAS-M and 50% compound (1 -1) and HPMCAS-MG.

[0047] Figure 6 illustrates modified differential scanning calorimetry trace for a solid dispersion of 25% compound (1 -1 ) and PVP equilibrated under 75% relative humidity.

[0048] Figures 7 A and 7B illustrate plasma concentration versus time curves for Compound (1 - 1 ) after 1 mg/kg intravenous dosing (solid rectangles) and 3 mg/kg oral dosing as 25% Compound (1 -1):PVP (open circles), 25% Compound (1 -1):HPMCAS-MG (open triangles), and 50%

Compound (1 -1):HPMCAS-MG (open inverted triangles). The inset depicts the same data plotted on a semilogarithmic scale.

[0049] Figures 8 A and 8B illustrate plasma concentration versus time curves for Compound (1 - 1 ) after 3 mg/kg oral dosing as 25% Compound (1 -1):PVP (open circles), 25% Compound (1 - 1):HPMCAS-MG (open triangles), and 50% Compound (1 -1 ):HPMCAS-MG (open inverted triangles). The inset depicts the same data plotted on a semi-logarithmic scale.

[0050] Figure 9 illustrates a powder X-ray diffraction profile of solid dispersions of compound (1 -1) in HPMCAS-MG at time zero of a stability test.

[0051] Figure 10 illustrates a powder X-ray diffraction profile of solid dispersions of compound (1 -1) in HPMCAS-MG after 1 month at 40 °C and 75 % relative humidity.

[0052] Figure 1 1 illustrates a powder X-ray diffraction profile of solid dispersions of compound (1 -1) in HPMCAS-MG after 2 months at 40 °C and 75 % relative humidity.

[0053] Figure 12 illustrates a powder X-ray diffraction profile of solid dispersions of compound (1 -1) in HPMCAS-MG after 3 month at 40 °C and 75 % relative humidity.

[0054] Figures 13A-13C illustrate kinetics of apoptosis induced by compound (1 -1) in ALL cell lines: Jurkat, RS 4-1 1 and TOM-1 cells, which were harvested at different time points after treatment. Apoptotic cells were defined as annexin V + with or without PI uptake. X-axis indicates doses of compound (1 -1) and Y-axis indicates percentage of apoptotic cells. One representative experiment of three is shown. [0055] Figures 14A-14D illustrate kinetics of apoptosis induced by compound (1 -1 ) in AML cell lines: HL60, K562, KG1 and KGla cells, which were harvested at different time points after treatment. Apoptotic cells were defined as annexin V + with or without PI uptake. X-axis, indicates doses of compound (1 -1) and Y-axis indicates percentage of apoptotic cells. One representative experiment of two is shown.

[0056] Figures 15A-15C illustrate cell cycle alterations induced by Compound (1 -1 ) in ALL and AML cell lines. Representative histograms of flow cytometry profiles of untreated HL60 and cells treated for 24 h with 100 nM of Compound (1 -1 ) (A). Cells were incubated with PI prior to cell cycle analysis. Cell cycle alterations for ALL (Figure 15B) and AML (Figure 15C) cell lines. X- axis indicates cell lines amd Y-axis indicates percentage of cells in cell cycle phase.

[0057] Figure 16 illustrates apoptosis induced by lower doses of Compound (1 -1). KG1 cells were incubated with 10 nM of Compound (1 -1). Apoptotic cells were defined as Snnexin V+ with or without PI uptake. Representative dot plots are shown (PI: FL2, Annexin V: FL1).

[0058] Figures 17A-17C illustrate BRD gene expression in leukemia cell lines and patient samples. Expression levels of BRD2, BRD3 and BRD4 in leukemia cell lines (Figure 17 A) and patient samples from ALL (Figure 17B) and AML (Figure 17C). X-axis indicates cell lines and Y- axis, indicates cDNA quantities, relative to ABL. CD34+ cells were obtained by positive selection with magnetic beads.

[0059] Figures 18A and 18B illustrate down regulation of BRD proteins and c-MYC upon Compound (1 -1 ) treatment. Cell lysates and cDNA extractions were obtained from different ALL and AML cell lines. Protein and cDNA levels were studied by immunoblot (Figure 18A) and QT- PCR (Figure 17B).

[0060] Figures 19A-19D illustrate cDNA kinetics of BRD2, BRD3, BRD4 after treatment with Compound (1 -1 ). cDNA extractions were obtained from different ALL and AML cell lines.

Expression levels were studied by QT-PCR.

[0061] Figure 20 illustrates Compound (1 -1 ) effects on primary cells. CD34+ and CD34- cord blood cells and AML cells were obtained by positive selection with magnetic antibody-labeled beads. Cells were treated with different doses of Compound (1 -1) and harvested after 24 hours. The Y-axis depicts annexin V with or without PI uptake.

[0062] Figures 21A-21T illustrate flow cytometric analysis of apoptosis in ALL cell lines (Jurkat, and RS 4-1 1) and AML cell lines (HL60 and K562) at 96 hours after short exposure to Compound (1 -1 ) at concentrations of 10 nM and 100 nM. [0063] Figures 22A-22L illustrate flow cytometric analysis of apoptosis in AML cell line HL60 after short exposure to Compound (1 -1) at concentrations of 0 nM, 1 nM, and 10 nM.

[0064] Figures 23A, 23B and 23C illustrate apoptosis for HL60 cell line of Figures 22A-22L.

[0065] Figures 24A and 24B illustrate apoptosis for HL60 and K562 cell lines.

[0066] Figures 25 A and 25B illustrate apoptosis for KG1 and KG la cell lines

[0067] Figures 26 A and 26B illustrate apoptosis for Jurkat and RS4-1 1 cell lines.

[0068] Figure 27 illustrates apoptosis for the TOM1 cell line.

[0069] Figure 28 is a plot of apoptosis after drug washout from Jurkat cell line.

[0070] Figures 29A and 29B are plots of apoptosis after drug washout from HL60 and K562 cells.

[0071] Figures 30A and 30B are plots of apoptosis after drug washout from Jurkat and RS4-1 1 cells.

[0072] Figures 31A and 3 IB illustrate an MTT assay in three ALL cell lines (Jurkat, RS 4-1 1 , TOM-1) and four AML cell lines (HL60, K562, KG1 and KGla).

[0073] Figures 32A-32C show apoptosis patterns in AML patients after treatment with

Compound (1 -1 ).

[0074] Figures 33A-33G show apoptosis patterns in AMLpatients.

[0075] Figures 34A and 34B show apoptosis patterns in AMLpatients.

[0076] Figure 35 illustrates c-MYC kinetics in AML and ALL cell lines upon treatment with Compound (1 -1 ).

[0077] Figure 36 illustrates BRD4 kinetics in AML and ALL cell lines upon treatment with Compound (1 -1 ).

[0078] Figure 37 illustrates BRD2 kinetics in AML and ALL cell lines upon treatment with Compound (1 -1 ).

[0079] Figure 38 illustrates BRD3 kinetics in AML and ALL cell lines upon treatment with Compound (1 -1 ).

[0080] Figures 39A-39C illustrate kinetics of apoptosis induced by different doses of Compound (1 -1) in AML and ALL cell lines. Myeloid and lymphoid cell lines were harvested at 72h after treatment with increasing doses of Compound (1 -1). Apoptotic cells were defined as annexin V+ with or without PI uptake. X-axis indicates doses of Compound (1 -1) and Y-axis indicates percentage of apoptotic cells. Results are shown with mean ± SD from duplicates of three independent experiments in AML and ALL cell lines upon treatment with Compound (1-1). [0081] Figures 40A-40H illustrate cell cycle alterations induced by with Compound (1 -1 ) (OTX015) in leukemia cell lines. Representative histograms of flow cytometry profiles of RS4-1 1 cells treated with increasing doses of OTX015 for 48h are shown Figures 40A-40F. Cells were incubated lh with PI prior to cell cycle analysis. Cell cycle alterations for all AML and ALL cell lines were analyzed at 48h in Figure 40G. X-axis indicates cell lines and Y-axis indicates percentage of cells in Gl and S-phase. Results are shown with mean ± SD from duplicates of three independent experiments.

[0082] Figures 41A and 41B illustrate gene expression of bromo domains in leukemia cell lines and modulation by Compound (1 -1) (OTX015). The different cell lines expressed BRD2, BRD3 and BRD4 at heterogeneous levels as detected by RQ-PCR with bcr-abl driven cell lines BV-173 and K562 having the lowest gene expression levels (Figure 41A).

[0083] Figures 41 C-41 H illustrate modulation of BRD4, BRD2 and BRD3 at the cD A level by OTX015 treatment at 250 nM and 500 nM respectively at 48h. Significant upregulation of BRD3 and BRD2 in KG1 , K562 and Jurkat and increase of BRD2 in KG1 and HL60 were detected. Gene expression levels of BRD4, BRD2, and BRD3 in leukemia cell lines at baseline levels are shown in Figures 41A and 41B. Gene expression levels after 48h exposure to OTX015 at 250 nM and 500 nM: of BRD4 (Figures 41 C and 41D), of BRD3 (Figures 41E and 41F), and of BRD2 (Figures 41G and 41H). X-axis indicates cell lines and Y-axis indicates cDNA quantities, relative to ABL.

Results are shown with mean ± SD from duplicates of two independent experiments.

[0084] Figures 42A-42D illustrates OTX015 inducing downregulation of c-MYC in all cell lines. Basal gene expression levels of c-MYC in different leukemia cell lines are shown Figures 42A and 42B). Different leukemia cell lines treated with 250 nM and 500 nM of OTX015 and c- MYC downregulation detected by QT-PCR at 48h are shown in Figures 42C and 42D.

[0085] Figures 43A-43L illustrate effects of OTX015 at the protein level for BRD 4, BRD2 and BRD 3 as well as c-MYC. In the selected AML cell line HL60 BRD4 and BRD3 remained unaffected after 72h OTX015 exposure at 500 nM with a transient downregulation of c-MYC observed after 24h-treatment (Figure 43A-43C) while the almost resistant AML cell line K562 displayed downregulation of BRD4, BRD3 and c-MYC starting after 24h exposure (Figure 43D- 43F). For the sensitive ALL cell lines, Jurkat displayed c-MYC downregulation at 48h and 72h (Figure 43G-43I) while BRD4, BRD3 and c-MYC remained unaffected in RS4-1 1 (Figure 4JD- 43L). AML cell lines HL60, K562 (Figure 43A-43C; Figure 43D-43F) and ALL cell lines Jurkat and RS4-1 1 (Figure 43G-43I; Figure 4JD-43L) were treated with OTX015 at 500 nM and compared to controls exposed to according DMSO. At indicated time -points proteins were extracted and immunoblotted with BRD4, BRD3, BPvD2 or c-MYC antibodies after gel electrophoresis. Blots were revealed for BRD4, BRD3, c-MYC and GAPDH either with the ODYSSEY (LiCor) technique which allows exact quantification of proteins related to GAPDH or BRD2 which was revealed by chemiluminescence. This technique did not allow protein quantification. One representative experiment out of three is shown.

[0086] Figures 44A-44D show effects of OTX015 on primary patient cells. 5 samples from AML patients and 2 ALL, including 1 ALL Ph+ patient, were treated ex vivo with OTX015. Patient characteristics are shown in Figure 44D. OTX015 induced apoptosis in primary AML patient samples at various degrees ranging from 35-85% (Figure 6). The Ph+ ALL patient appeared to be resistant. OTX015 induced apoptosis in primary cells of the AML and ALL patients. Mononuclear cells were obtained from bone marrow (BM) or peripheral blood (PB) from AML and ALL patients. Cells were exposed 72h with 250 and 500 nM of OTX015 and apoptosis was assessed by annexin V and PI staining. Results are shown with means ± SD from duplicates of one experiment.

[0087] Figures 45A-45E illustrate modulation of c-MYC at the protein level in a patient sample. Protein extracts were obtained from bone marrow (BM) cells of patient 5 (Figure 44D; Figures 45A- 45D) upon ex vivo treatment with 250 and 500 nM of OTX015 respectively. The BM cells displayed downregulation of c-MYC after 72h exposure to OTX015. Bone marrow cells from patient 5 were treated with OTX015 at 250 nM and 500 nM and compared to controls exposed to according concentrations with DMSO. Proteins were extracted at 72h and immunoblotted with appropriate c-MYC antibodies after gel electrophoresis. Blots were revealed with the ODYSSEY (LiCor) technique which allowed exact quantification of proteins related to GAPDH (Figure 45 A). Expression level of cMYC relative to ABL were realised by RQ-PCR at three time points 24, 48 and 72h (Figure 45B). Results in Figure 45B are shown with means ± SD from duplicates.

[0088] Figure 46 illustrates a summary of biological effects of OTX015.

[0089] Figures 47A-47D illustrate basal gene expression of BRD2, BRD3 and BRD4 in patient samples as assessed by RQ-PCR analysis. Among ALL patients, Ph+ ALL showed lower BRD expression levels (Figures 47 A and 47B; patients 3 to 6 in Figure 47E) while BRD expression levels among AML patients were more heterogeneous (Figure 47C and 47D).

[0090] Figure 47E provides a summary of characteristics of the patients whose samples were assessed to give the results in Figures 47A-47D. DETAILED DESCRIPTION OF THE INVENTION

[0091] The present subject matter will now be described more fully hereinafter with reference to the accompanying Figures and Examples, in which representative embodiments are shown. The present subject matter can, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided to describe and enable one of skill in the art. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the subject matter pertains. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entireties.

[0092] The present inventions described herein provide for methods of treating acute lymphoblastic leukemia, acute myeloid leukemia , BCR-ABL positive acute lymphoblastic leukemia and CD34 positive acute myeloid leukemia. The detailed description sets forth the disclosure in various parts: I. Thienotriazolodiazepine Compounds; II. Formulations; III. Dosage Forms; IV. Dosage; V. Process; and VI. Examples. One of skill in the art would understand that each of the various embodiments of methods of treatment include the various embodiments of

thienotriazolodiazepine compounds, formulations, dosage forms, dosage and processes described herein.

[0093] In one aspect, the present invention provides a method of treating acute lymphoblastic leukemia comprising the step of administering to a patient a pharmaceutically acceptable amount of a composition comprising a thienotriazolodiazepine compound, as described herein, formed as a solid dispersion comprising an amorphous thienotriazolodiazepine compound and a

pharmaceutically acceptable salt thereof or a hydrate thereof; and a pharmaceutically acceptable polymer. Various embodiments of such a solid dispersion are described herein and can be used accordingly.

[0094] In one aspect, the present invention provides a method of treating acute myeloid leukemia comprising the step of administering to a patient a pharmaceutically acceptable amount of a composition comprising a thienotriazolodiazepine compound, as described herein, formed as a solid dispersion comprising an amorphous thienotriazolodiazepine compound and a

pharmaceutically acceptable salt thereof or a hydrate thereof; and a pharmaceutically acceptable polymer. Various embodiments of such a solid dispersion are described herein and can be used accordingly. [0095] In one aspect, the present invention provides a method of treating a BCR-ABL positive acute lymphoblastic leukemia comprising the step of administering to a patient a pharmaceutically acceptable amount of a composition comprising a thienotriazolodiazepine compound according to the various embodiments described herein. In some embodiments of the method of treating a BCR- ABL positive acute lymphoblastic leukemia, the thienotriazolodiazepine compound, as described herein, is formed as a solid dispersion comprising an amorphous thienotriazolodiazepine compound and a pharmaceutically acceptable salt thereof or a hydrate thereof; and a pharmaceutically acceptable polymer. Various embodiments of such a solid dispersion are described herein and can be used accordingly.

[0096] In one aspect, the present invention provides a method of treating a CD34 positive acute myeloid leukemia comprising the step of administering to a patient a pharmaceutically acceptable amount of a composition comprising a thienotriazolodiazepine compound according to the various embodiments described herein. In some embodiments of the method of treating a CD34 positive acute myeloid leukemia, the thienotriazolodiazepine compound, as described herein, is formed as a solid dispersion comprising an amorphous thienotriazolodiazepine compound and a

pharmaceutically acceptable salt thereof or a hydrate thereof; and a pharmaceutically acceptable polymer. Various embodiments of such a solid dispersion are described herein and can be used accordingly.

I. Thienotriazolodiazepine Compounds: [0097] In one embodiment, the thienotriazolodiazepine compounds, used in the formulations of the present invention, are represented by Formula (1):

1 · 2

wherein R is alkyl having a carbon number of 1 -4, R is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1 -4 optionally substituted by a halogen atom or a hydro xyl group, R ³ is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1 - 4, alkoxy having a carbon number of 1 -4 or cyano;— NR ⁵ — (CH2) _m — R ⁶ wherein R ⁵ is a hydrogen atom or alkyl having a carbon number of 1 -4, m is an integer of 0-4, and R ⁶ is phenyl or pyridyl optionally substituted by a halogen atom; or -NR ⁷ — CO— (CH ₂ ) _n — R ⁸ wherein R ⁷ is a hydrogen atom or alkyl having a carbon number of 1 -4, n is an integer of 0-2, and R is phenyl or pyridyl optionally substituted by a halogen atom, and R ⁴ is— (CH ₂ ) _a — CO— NH— R ⁹ wherein a is an integer of 1 -4, and R ⁹ is alkyl having a carbon number of 1 -4; hydro xyalkyl having a carbon number of 1 -4; alkoxy having a carbon number of 1 -4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1 -4, alkoxy having a carbon number of 1 -4, amino or a hydro xyl group or

— (CH ₂ ) _b — COOR ¹⁰ wherein b is an integer of 1 -4, and R ¹⁰ is alkyl having a carbon number of 1 -4, including any salts, isomers, enantiomers, racemates, hydrates, solvates, metabolites, and polymorphs thereof.

[0098] In one embodiment, a suitable alkyl group includes linear or branched alkyl radicals including from 1 carbon atom up to 4 carbon atoms. In one embodiment, a suitable alkyl group includes linear or branched alkyl radicals including from 1 carbon atom up to 3 carbon atoms. In one embodiment, a suitable alkyl group includes linear or branched alkyl radicals include from 1 carbon atom up to 2 carbon atoms. In one embodiment, exemplary alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl. In one embodiment, exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-l -propyl, and 2-methyl-2 -propyl.

[0099] In some embodiments, the present invention provides pharmaceutically acceptable salts, solvates, including hydrates, and isotopically-labeled forms of the thienotriazolodiazepine compounds described herein. In one embodiment, pharmaceutically acceptable salts of the thienotriazolodiazepine compounds include acid addition salts formed with inorganic acids. In one embodiment, pharmaceutically acceptable inorganic acid addition salts of the

thienotriazolodiazepine include salts of hydrochloric, hydrobromic, hydroiodic, phosphoric, metaphosphoric, nitric and sulfuric acids. In one embodiment, pharmaceutically acceptable salts of the thienotriazolodiazepine compounds include acid addition salts formed with organic acids. In one embodiment, pharmaceutically acceptable organic acid addition salts of the thienotriazolodiazepine include salts of tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, formic, propionic, glycolic, gluconic, maleic, succinic, camphorsulfuric, isothionic, mucic, gentisic, isonicotinic, saccharic, glucuronic, furoic, glutamic, ascorbic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, stearic, sulfinilic, alginic, galacturonic and arylsulfonic, for example benzenesulfonic and 4-methyl benzenesulfonic acids.

[00100] Representative thienotriazolodiazepine compounds of Formula (1) include, but are not limited to, the thienotriazolodiazepine compounds (1-1) to (1 -18), which are listed in the following Table A.

[00101] Compound (1-1), of Table A, will be referred to herein as OTX-015 or Y803.

[00102] Table A: Exemplary compounds of the invention:

(1-5) (1-6)

(1-7) (1-8)

[00103] In some embodiments, thienotriazolodiazepme compounds of Formula (1) include (i) (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl^

N-(4-hydroxyphenyl)acetamide or a dihydrate thereof, (ii) methyl (S)-{4-(3'-cyanobiphenyl-4-yl)- 2,3,9-trimethyl-6H-thieno[3,2-fJ[l ,2,4]tri- azolo[4,3-a][l ,4]diazepin-6-yl} acetate, (iii) methyl (S)- {2,3,9-trimethyl-4-(4-phenylaminophenyl)-6H-thieno[3,2-fJ[l ,2,4]triaz- olo[4,3-a][l,4]diazepin-6- yl} acetate; and (iv) methyl (S)-{2,3,9-trimethyl-4-[4-(3-phenylpropionylamino)phenyl]-6H - thieno[3,2-f- ][l ,2,4]triazolo[4,3-a][l,4]diazepin-6-yl} acetate.

[00104] In some embodiments, thienotriazolodiazepme compounds of Formula (1) include (S)-2- [4-(4-chlorophenyl)-2,3,9-trimethyl-6H hieno[3,2-fJ[l ,2,-4]triazolo[4,3-a][l,4]diazepin-6-yl]-N-(4- hydroxyphenyl)acetamide dihydrate. [00105] In some embodiments, thienotriazolodiazepine compounds of Formula (1) include (S)-2-

[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-to

hydroxypheny 1) acetamide .

II. Formulations: [00106] The compound of Formula (1) presents highly specific difficulties in relation to administration generally and the preparation of galenic compositions in particular, including the particular problems of drug bioavailability and variability in inter- and intra-patient dose response, necessitating development of a non-conventional dosage form with respect to the practically water- insoluble properties of the compound.

[00107] Previously, it had been found that the compound of Formula (1) could be formulated as a solid dispersion with the carrier ethyl acrylate-methyl methacrylate-trimethylammonioethyl methacrylate chloride copolymer (Eudragit RS, manufactured by Rohm) to provide an oral formulation that preferentially released the pharmaceutical ingredient in the lower intestine for treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease (US Patent Application 20090012064 Al , published Jan 8, 2009). It was found, through various experiments, including animal tests, that in inflammatory bowel diseases drug release in a lesion and a direct action thereof on the inflammatory lesion were more important than the absorption of the drug into circulation from the gastrointestinal tract.

[00108] It has now been unexpectedly found that thienotriazolodiazepine compounds, according to Formula (1), pharmaceutically acceptable salts, solvates, including hydrates, racemates, enantiomers isomers, and isotopically-labeled forms thereof, can be formulated as a solid dispersion with pharmaceutically acceptable polymers to provide an oral formulation that provides high absorption of the pharmaceutical ingredient into the circulation from the gastrointestinal tract for treatment of diseases other than inflammatory bowel diseases. Studies in both dogs and humans have confirmed high oral bioavailability of these solid dispersions compared with the Eudragit solid dispersion formulation previously developed for the treatment of inflammatory bowel disease.

[00109] Solid dispersions are a strategy to improve the oral bioavailability of poorly water soluble drugs.

[00110] The term "solid dispersion" as used herein refers to a group of solid products including at least two different components, generally a hydrophilic carrier and a hydrophobic drug, the thienotriazolodiazepine compounds, according to Formula (1). Based on the drug's molecular arrangement within the dispersion, six different types of solid dispersions can be distinguished. Commonly, solid dispersions are classified as simple eutectic mixtures, solid solutions, glass solution and suspension, and amorphous precipitations in a crystalline carrier. Moreover, certain combinations can be encountered, for example, in the same sample some molecules may be present in clusters while some are molecularly dispersed.

[00111] In one embodiment, the thienotriazolodiazepine compounds, according to Formula (1) can be dispersed molecularly, in amorphous particles (clusters). In another embodiment, the thienotriazolodiazepine compounds, according to Formula (1) can be dispersed as crystalline particles. In one embodiment, the carrier can be crystalline. In another embodiment, the carrier can be amorphous.

[00112] In one embodiment, the present invention provides a pharmaceutical composition comprising a solid dispersion of a thienotriazolodiazepine compound, in accordance with Formula (1), or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof; and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is hypromellose acetate succinate (also called hydroxypropylmethylcellulose acetate succinate or HPMCAS). In one embodiment, the dispersion has a thienotriazolodiazepine compound to hydroxypropylmethylcellulose acetate succinate (HPMCAS) weight ratio of 1 :3 to 1 : 1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 130 °C to 140 °C. In other such embodiments, the single Tg occurs at about 135 °C. In some such

embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1). For the purpose of this application "substantially free" shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound of Formula (1). In some embodiments, the hydroxypropylmethyl cellulose acetate succinates (HPMCAS), may include M grade having 9% acetyl/11% succinoyl (e.g., HPMCAS having a mean particle size of 5 μηι (i.e., HPMCAS-MF, fine powder grade) or having a mean particle size of 1 mm (i.e., HPMCAS-MG, granular grade)), H grade having 12% acetyl/6% succinoyl (e.g., HPMCAS having a mean particle size of 5 μηι (i.e., HPMCAS-HF, fine powder grade) or having a mean particle size of 1 mm (i.e., HPMCAS-HG, granular grade)), and L grade having 8% acetyl/15% succinoyl (e.g., HPMCAS having a mean particle size of 5 μηι (i.e., HPMCAS-LF, fine powder grade) or having a mean particle size of 1 mm (i.e., HPMCAS-LG, granular grade).

[00113] In one embodiment, the present invention provides a pharmaceutical composition comprising a solid dispersion of a thienotriazolodiazepine compound of Formula (1) or a

pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof in a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is polyvinylpyrrolidone (also called povidone or PVP). In one embodiment, the dispersion has a thienotriazolodiazepine compound to PVP weight ratio of 1 :3 to 1 : 1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 175 °C to about 185 °C. In other such embodiments, the single Tg occurs at about 179 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1). For the purpose of this application "substantially free" shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-th eta associated with crystalline thienotriazolodiazepine compound of Formula (1). In some embodiments, the polyvinyl pyrrolidones may have molecular weights of about 2,500 (Kollidon ® 12 PF, weight-average molecular weight between 2,000 to 3,000), about 9,000 (Kollidon® 17 PF, weight-average molecular weight between 7,000 to 11,000), about 25,000 (Kollidon® 25, weight-average molecular weight between 28,000 to 34,000), about 50,000 (Kollidon® 30, weight-average molecular weight between 44,000 to 54,000), and about 1 ,250,000 (Kollidon® 90 or Kollidon® 90F, weight-average molecular weight between 1,000,000 to 1 ,500,000).

[00114] In one embodiment, a pharmaceutical composition of the present invention comprises a solid dispersion of an amorphous form of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is hypromellose acetate succinate. In one embodiment, the weight ratio of thienotriazolodiazepine compound of Formula (1) to hypromellose acetate succinate ranges from 1 : 3 to 1 : 1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 130 °C to 140 °C. In other such embodiments, the single Tg occurs at about 135 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1). For the purpose of this application "substantially free" shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound of Formula (1).

[00115] In one embodiment, a pharmaceutical composition of the present invention comprises a solid dispersion of an amorphous form of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is polyvinylpyrrolidone. In one embodiment, the weight ratio of thienotriazolodiazepine compound of Formula (1) to polyvinylpyrrolidone ranges from 1 :3 to 1 : 1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 175 °C to about 185 °C. In other such embodiments, the single Tg occurs at about 179 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1). For the purpose of this application "substantially free" shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound of Formula (1).

[00116] In one embodiment, a pharmaceutical composition of the present invention comprises a solid dispersion of a crystalline form of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is hypromellose acetate succinate. In one embodiment, the weight ratio of thienotriazolodiazepine compound of Formula (1) to hypromellose acetate succinate ranges from 1 :3 to 1 : 1.

[00117] In one embodiment, a pharmaceutical composition of the present invention comprises a solid dispersion of a crystalline form of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is polyvinylpyrrolidone. In one embodiment, the weight ratio of thienotriazolodiazepine compound of Formula (1) to polyvinylpyrrolidone ranges from 1 :3 to 1 : 1.

[00118] In some embodiments, a pharmaceutical composition comprising a solid dispersion is prepared by spray drying.

[00119] In one embodiment, a pharmaceutical composition of the present invention comprises a spray dried solid dispersion of a thienotriazolodiazepine compound of Formula (1) or a

pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is hypromellose acetate succinate. In one embodiment, the weight ratio of compound (1) to hypromellose acetate succinate ranges from 1 :3 to 1 :1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the

thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 130 °C to 140 °C. In other such embodiments, the single Tg occurs at about 135 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1). For the purpose of this application "substantially free" shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-th eta associated with crystalline thienotriazolodiazepine compound of Formula (1). [00120] In one embodiment, a pharmaceutical composition of the present invention comprises a spray dried solid dispersion of a thienotriazolodiazepine compound of Formula (1) or a

pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is polyvinylpyrrolidone. In one embodiment, the weight ratio of compound (1) to polyvinylpyrrolidone ranges from 1 :3 to 1 : 1. In one

embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 175 °C to 185 °C. In other such embodiments, the single Tg occurs at about 179 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1). For the purpose of this application "substantially free" shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound of Formula (1).

[00121] In one embodiment, a pharmaceutical composition of the present invention comprises a spray dried solid dispersion of an amorphous form of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is hypromellose acetate succinate. In one embodiment, the weight ratio of thienotriazolodiazepine compound of Formula (1) to hypromellose acetate succinate ranges from 1 :3 to 1 :1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 130 °C to 140 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In other such embodiments, the single Tg occurs at about 135 °C. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1). For the purpose of this application "substantially free" shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound of Formula (1).

[00122] In one embodiment, a pharmaceutical composition of the present invention comprises a spray dried solid dispersion of an amorphous form of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is polyvinylpyrrolidone. In one embodiment, the weight ratio of thienotriazolodiazepine compound of Formula (1) to polyvinylpyrrolidone ranges from 1 : 3 to 1 :1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 175 °C to 185 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In other such embodiments, the single Tg occurs at about 179 °C. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1). For the purpose of this application "substantially free" shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline

thienotriazolodiazepine compound of Formula (1).

[00123] In one embodiment, a pharmaceutical composition of the present invention comprises a spray dried solid dispersion of a crystalline form of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is hypromellose acetate succinate. In one embodiment, the weight ratio of thienotriazolodiazepine compound of Formula (1) to hypromellose acetate succinate ranges from 1 :3 to 1 : 1.

[00124] In one embodiment, a pharmaceutical composition of the present invention comprises a spray dried solid dispersion of a crystalline form of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is polyvinylpyrrolidone. In one embodiment, the weight ratio of thienotriazolodiazepine compound of Formula (1) to polyvinylpyrrolidone ranges from 1 :3 to 1 :1.

[00125] In one preferred embodiment, the present invention provides a pharmaceutical composition comprising a solid dispersion of 2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thienol[3,2-fj-[l ,2,4]triazolo[4,3-a][l,4]diazepin-6-yl]-N-(4-hydroxyphenyl)a cetamide dihydrate, compound (1-1):

or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is HPMCAS. In one embodiment, the dispersion has compound (1-1) and HPMCAS in a weight ratio of 1 :3 to 1 :1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is

homogeneously dispersed throughout the solid dispersion. In one embodiment, the solid dispersion is spray dried. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 130 °C to 140 °C. In other such embodiments, the single Tg occurs at about 135 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound (1-1). For the purpose of this application "substantially free" shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound (1-1).

[00126] In another embodiment, the pharmaceutical composition comprises a solid dispersion compound (1-1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form; and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is PVP. In one embodiment, the dispersion has compound (1-1) and PVP in a weight ratio 1 :3 to 1 : 1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In one embodiment, the solid dispersion is spray dried. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 175 °C to 185 °C. In other such embodiments, the single Tg occurs at about 179 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound (1-1). For the purpose of this application "substantially free" shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound (1-1).

[00127] In one embodiment, a pharmaceutical composition of the present invention comprises a solid dispersion of an amorphous form of a thienotriazolodiazepine compound (1 -1 ) or a

pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof; and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is HPMCAS. In one embodiment, the dispersion has compound (1-1) and HPMCAS in a weight ratio of 1 :3 to 1 :1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is

homogeneously dispersed throughout the solid dispersion. In one embodiment, the solid dispersion is spray dried. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 130 °C to 140 °C. In other such embodiments, the single Tg occurs at about 135 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound (1-1). For the purpose of this application "substantially free" shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound (1-1).

[00128] In one embodiment, a pharmaceutical composition of the present invention comprises a solid dispersion of an amorphous form of a thienotriazolodiazepine compound (1-1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof; and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is PVP. In one embodiment, the dispersion has compound ( 1 - 1 ) and PVP in a weight ratio 1 : 3 to 1 : 1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In one embodiment, the solid dispersion is spray dried. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 175 °C to 185 °C. In other such embodiments, the single Tg occurs at about 189 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound (1-1). For the purpose of this application "substantially free" shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound (1-1).

[00129] In one embodiment, a pharmaceutical composition of the present invention comprises a solid dispersion of a crystalline form of a thienotriazolodiazepine compound (1-1) or a

pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof; and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is HPMCAS. In one embodiment, the dispersion has compound (1-1) and HPMCAS in a weight ratio of 1 :3 to 1 :1. In one embodiment, the solid dispersion is spray dried.

[00130] In one embodiment, a pharmaceutical composition of the present invention comprises a solid dispersion of a crystalline form of a thienotriazolodiazepine compound (1-1) or a

pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof; and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is PVP. In one embodiment, the dispersion has compound (1-1) and PVP in a weight ratio 1 :3 to 1 : 1. In one embodiment, the solid dispersion is spray dried.

[00131] The solid dispersions of the invention, described herein, exhibit especially advantageous properties when administered orally. Examples of advantageous properties of the solid dispersions include, but are not limited to, consistent and high level of bioavailability when administered in standard bioavailability trials in animals or humans. The solid dispersions of the invention can include a solid dispersion comprising thienotriazolodiazepine compound of Formula (1) and a polymer and additives. In some embodiments, the solid dispersions can achieve absorption of the thienotriazolodiazepine compound of Formula (1) into the bloodstream that cannot be obtained by merely admixing the thienotriazolodiazepine compound of Formula (1) with additives since the thienotriazolodiazepine compound of Formula (1) drug has negligible solubility in water and most aqueous media. The bioavailability, of thienotriazolodiazepine compound of Formula (1) or of thienotriazolodiazepine compound (1-1) may be measured using a variety of in vitro and/or in vivo studies. The in vivo studies may be performed, for example, using rats, dogs or humans.

[00132] The bioavailability may be measured by the area under the curve (AUC) value obtained by plotting a serum or plasma concentration, of the thienotriazolodiazepine compound of Formula (1) or thienotriazolodiazepine compound (1-1), along the ordinate (Y-axis) against time along the abscissa (X-axis). The AUC value of the thienotriazolodiazepine compound of Formula (1) or thienotriazolodiazepine compound (1-1) from the solid dispersion, is then compared to the AUC value of an equivalent concentration of crystalline thienotriazolodiazepine compound of Formula (1) or crystalline thienotriazolodiazepine compound (1-1) without polymer. In some embodiments, the solid dispersion provides an area under the curve (AUC) value, when administered orally to a dog, that is selected from: at least 0.4 times, 0.5 times, 0.6 time, 0.8 time, 1.0 times, a corresponding AUC value provided by a control composition administered intravenously to a dog, wherein the control composition comprises an equivalent quantity of a crystalline thienotriazolodiazepine compound of Formula I.

[00133] The bioavailability may be measured by in vitro tests simulating the pH values of a gastric environment and an intestine environment. The measurements may be made by suspending a solid dispersion of the thienotriazolodiazepine compound of Formula (1) or thienotriazolodiazepine compound (1-1), in an aqueous in vitro test medium having a pH between 1.0 to 2.0, and the pH is then adjusted to a pH between 5.0 and 7.0, in a control in vitro test medium. The concentration of the amorphous thienotriazolodiazepine compound of Formula (1) or amorphous

thienotriazolodiazepine compound (1-1) may be measured at any time during the first two hours following the pH adjustment. In some embodiments, the solid dispersion provides a concentration, of the amorphous thienotriazolodiazepine compound of Formula (1) or amorphous

thienotriazolodiazepine compound (1-1), in an aqueous in vitro test medium at pH between 5.0 to 7.0 that is selected from: at least 5-fold greater, at least 6 fold greater, at least 7 fold greater, at least 8 fold greater, at least 9 fold greater or at least 10 fold greater, compared to a concentration of a crystalline thienotriazolodiazepine compound of Formula (1) or crystalline thienotriazolodiazepine compound (1-1), without polymer.

[00134] In other embodiments, the concentration of the amorphous thienotriazolodiazepine compound of Formula (1) or amorphous thienotriazolodiazepine compound (1-1), from the solid dispersion placed in an aqueous in vitro test medium having a pH of 1.0 to 2.0, is: at least 40%, at least 50% higher, at least 60 %, at least 70 %; at least 80 %, than a concentration of a crystalline thienotriazolodiazepine compound of Formula (1) without polymer. In some such embodiments, the polymer of the solid dispersion is HPMCAS. In some such embodiments, the polymer of the solid dispersion is PVP.

[00135] In other embodiments, a concentration of the amorphous thienotriazolodiazepine compound of Formula (1) or amorphous thienotriazolodiazepine compound (1-1), from the solid dispersion, is: at least 40%, at least 50% higher, at least 60 %, at least 70 %; at least 80 %, compared to a concentration of thienotriazolodiazepine compound of Formula (1), from a solid dispersion of thienotriazolodiazepine compound of the Formula (1) and a pharmaceutically acceptable polymer selected from the group consisting of: hypromellose phthalate and ethyl acrylate-methyl

methacrylate-trimethylammonioethyl methacrylate chloride copolymer, wherein each solid dispersion was placed in an aqueous in vitro test medium having a pH of 1.0 to 2.0. In some such embodiments, the polymer of the solid dispersion is HPMCAS. In some such embodiments, the polymer of the solid dispersion is PVP.

[00136] In some embodiments, the solid dispersions, described herein, exhibit stability against recrystallization of the thienotriazolodiazepine compound of the Formula (1) or the

thienotriazolodiazepine compound (1-1) when exposed to humidity and temperature over time. In one embodiment, the concentration of the amorphous thienotriazolodiazepine compound of the Formula (1) or the thienotriazolodiazepine compound (1-1) which remains amorphous is selected from: at least 90 %, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% and at least 99%.

III. Dosage Forms:

[00137] Suitable dosage forms that can be used with the solid dispersions of the present invention include, but are not limited to, capsules, tablets, mini-tablets, beads, beadlets, pellets, granules, granulates, and powder. Suitable dosage forms may be coated, for example using an enteric coating. Suitable coatings may comprise but are not limited to cellulose acetate phthalate, hydroxypropylmethylcellulose (HPMC), hydroxypropylmethylcellulose phthalate, a polymethylacrylic acid copolymer, or hydroxylpropylmethylcellulose acetate succinate (HPMCAS). In some embodiments, certain combinations can be encountered, for example, in the same sample some molecules of the thienotriazolodiazepine of the present invention may be present in clusters while some are molecularly dispersed with a carrier.

[00138] In some embodiments, the solid dispersions of the invention may be formulated as tablets, caplets, or capsules. In one some embodiments, the solid dispersions of the invention may be formulated as mini-tablets or pour-into-mouth granules, or oral powders for constitution. In some embodiments, the solid dispersions of the invention are dispersed in a suitable diluent in combination with other excipients (e.g., re-crystallization/precipitation inhibiting polymers, taste- masking components, etc) to give a ready-to-use suspension formulation. In some embodiments, the solid dispersions of the invention may be formulated for pediatric treatment.

[00139] In one embodiment, the pharmaceutical composition of the present invention is formulated for oral administration. In one embodiment, the pharmaceutical composition comprises a solid dispersion, according to the various embodiments described herein, comprising a

thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof; and a polymer carrier. In one embodiment, the pharmaceutical composition further includes one or more additives such as disintegrants, lubricants, glidants, binders, and fillers.

[00140] Examples of suitable pharmaceutically acceptable lubricants and pharmaceutically acceptable glidants for use with the pharmaceutical composition include, but are not limited to, colloidal silica, magnesium trisilicate, starches, talc, tribasic calcium phosphate, magnesium stearate, aluminum stearate, calcium stearate, magnesium carbonate, magnesium oxide, polyethylene glycol, powdered cellulose, glyceryl behenate, stearic acid, hydrogenated castor oil, glyceryl monostearate, and sodium stearyl fumarate.

[00141] Examples of suitable pharmaceutically acceptable binders for use with the

pharmaceutical composition include, but are not limited to starches; celluloses and derivatives thereof, e.g., microcrystalline cellulose (e.g., AVICEL PH from FMC), hydroxypropyl cellulose, hydroxyethyl cellulose, and hydroxylpropylmethylcellulose (HPMC, e.g., METHOCEL from Dow Chemical); sucrose, dextrose, corn syrup; polysaccharides; and gelatin.

[00142] Examples of suitable pharmaceutically acceptable fillers and pharmaceutically acceptable diluents for use with the pharmaceutical composition include, but are not limited to, confectioner's sugar, compressible sugar, dextrates, dextrin, dextrose, lactose, mannitol, micro crystalline cellulose (MCC), powdered cellulose, sorbitol, sucrose, and talc.

[00143] In some embodiments, excipients may serve more than one function in the

pharmaceutical composition. For example, fillers or binders may also be disintegrants, glidants, anti-adherents, lubricants, sweeteners and the like.

[00144] In some embodiments, the pharmaceutical compositions of the present invention may further include additives or ingredients, such as antioxidants (e.g., ascorbyl palmitate, butylated hydroxylanisole (BHA), butylated hydroxytoluene (BHT), a-tocopherols, propyl gallate, and fumaric acid), antimicrobial agents, enzyme inhibitors, stabilizers (e.g., malonic acid), and/or preserving agents.

[00145] Generally, the pharmaceutical compositions of the present invention may be formulated into any suitable solid dosage form. In some embodiments, the solid dispersions of the invention are compounded in unit dosage form, e.g., as a capsule, or tablet, or a multi-particulate system such as granules or granulates or a powder, for administration.

[00146] In one embodiment, a pharmaceutical compositions includes a solid dispersion of a thienotriazolodiazepine compound of Formula (1), according to the various embodiments of solid dispersions described herein, and hydroxypropylmethylcellulose acetate succinate (HPMCAS), wherein the thienotriazolodiazepine compound is amorphous in the solid dispersion and has a thienotriazolodiazepine compound to hydroxypropylmethylcellulose acetate succinate (HPMCAS), weight ratio of 1 :3 to 1 : 1; 45 -50 wt. % of lactose monohydrate; 35-40 wt. % of microcrystalline cellulose; 4-6 wt. % of croscarmellose sodium; 0.8-1.5 wt. % of colloidal silicon dioxide; and 0.8- 1.5 wt. % of magnesium stearate.

IV. Dosage:

[00147] In one embodiment, the present invention provides a pharmaceutical composition that maybe formulated into any suitable solid dosage form. In one embodiment, a pharmaceutical composition in accordance with the present invention comprises one or more of the various embodiments of the thienotriazolodiazepine of Formula (1) as described herein in a dosage amount ranging from about 10 mg to about 100 mg. In one embodiment, the pharmaceutical composition of the present invention includes one or more of the various embodiments of the

thienotriazolodiazepine of Formula (1) as described herein in a dosage amount selected from the group consisting of from about 10 mg to about 100 mg, about 10 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 70 mg, about 10 mg to about 60 mg, about 10 mg to about 50 mg, about 10 mg to about 40 mg, about 10 mg to about 30 mg, and about 10 mg to about 20 mg. In one embodiment, the pharmaceutical composition of the present invention includes one or more of the various embodiments of the thienotriazolodiazepine of Formula (1) as described herein in a dosage amount selected from the group consisting of about 10 mg, about 50 mg, about 75 mg, about 100 mg.

[00148] In some embodiments, the methods of the present invention includes administering to a subject in need thereof one or more of the various embodiments of the thienotriazolodiazepine of Formula (I) as described herein in a dosage amount selected from the group consisting of about 1 mg, about 2 mg, about 2.5 mg, about 3 mg, about 4 mg, about 5 mg, about 7.5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 1 10 mg, about 120 mg, about 130 mg, about 140 mg, and about 150 mg, and in a dosage form selected from the group consisting of once weekly, once daily every sixth day, once daily every fifth day, once daily every fourth day, once daily every third day, once daily every other day, once daily, twice daily, three times daily, four times daily, and five times daily. In another embodiment, any of the foregoing dosage amounts or dosage forms is decreased periodically or increased periodically.

[00149] In some embodiments, the methods of the present invention includes administering to a subject in need thereof a thienotriazolodiazepine selected from the group consisting of compounds (1-1), (1 -2), (1-3), (1-4), (1 -5), (1-6), (1-7), (1 -8), (1-9), (1-10), (1-11), (1-12), (1-13), (1-14), (1-15), (1-16), (1-17), and (1-18), in a dosage amount selected from the group consisting of about 1 mg, about 2 mg, about 2.5 mg, about 3 mg, about 4 mg, about 5 mg, about 7.5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, and about 150 mg, and in a dosage form selected from the group consisting of once weekly, once daily every sixth day, once daily every fifth day, once daily every fourth day, once daily every third day, once daily every other day, once daily, twice daily, three times daily, four times daily, and five times daily. In another embodiment, any of the foregoing dosage amounts or dosage forms is decreased periodically or increased periodically. [00150] Such unit dosage forms are suitable for administration 1 to 5 times daily depending on the particular purpose of therapy, the phase of therapy, and the like. In one embodiment, the dosage form may be administered to a subject in need thereof at least once daily for at least two successive days. In one embodiment, the dosage form may be administered to a subject in need thereof at least once daily on alternative days. In one embodiment, the dosage form may be administered to a subject in need thereof at least weekly and divided into equal and/or unequal doses. In one embodiment, the dosage form may be administered to a subject in need thereof weekly, given either on three alternate days and/or 6 times per week. In one embodiment, the dosage form may be administered to a subject in need thereof in divided doses on alternate days, every third day, every fourth day, every fifth day, every sixth day and/or weekly. In one embodiment, the dosage form may be administered to a subject in need thereof two or more equally or unequally divided doses per month.

[00151] The dosage form used, e.g., in a capsule, tablet, mini-tablet, beads, beadlets, pellets, granules, granulates, or powder may be coated, for example using an enteric coating. Suitable coatings may comprise but are not limited to cellulose acetate phthalate,

hydroxypropylmethylcellulose (HPMC), hydro xypropylmethylcellulose phthalate, a

polymethylacrylic acid copolymer, or hydroxylpropylmethylcellulose acetate succinate (HPMCAS).

V. Process:

[00152] The thienotriazolodiazepine compounds disclosed herein can exist as free base or as acid addition salt can be obtained according to the procedures described in US Patent Application

Publication No. 2010/0286127, incorporated by reference in its entirety herein, or in the present application. Individual enantiomers and diastereomers of the thienotriazolodiazepine compounds of the present invention can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art.

[00153] In some embodiments, a one or more of the various embodiments for the formulation of the thienotriazolodiazepine, according to Formula (1), is prepared by a solvent evaporation method. In one embodiment, the solvent evaporation method comprises solubilization of a

thienotriazolodiazepine compound, according to Formula (1), carrier in a volatile solvent that is subsequently evaporated. In one embodiment, the volatile solvent may one or more excipients. In one embodiment, the one or more excipients include, but are not limited to anti-sticking agents, inert fillers, surfactants wetting agents, pH modifiers and additives. In one embodiment, the excipients may dissolved or in suspended or swollen state in the volatile solvent.

[00154] In one embodiment, preparation of solid dispersions in accordance with the present invention includes drying one or more excipients suspended in a volatile solvent. In one

embodiment, the drying includes vacuum drying, slow evaporation of the volatile solvent at low temperature, use of a rotary evaporator, spray-drying, spray granulation, freeze-drying, or use of supercritical fluids.

[00155] In one embodiment, spray drying preparation of a formulation for the

thienotriazolodiazepine composition, according to Formula (1), is used which involves atomization of a suspension or a solution of the composition into small droplets, followed by rapid removal solvent from the formulation. In one embodiment, preparation of a formulation in accordance with the present invention involves spray granulation in which a solution or a suspension of the composition in a solvent is sprayed onto a suitable chemically and/or physically inert filler, such as lactose or mannitol. In one embodiment, spray granulation of the solution or the suspension of the composition is achieved via two-way or three-way nozzles.

[00156] The invention is illustrated in the following non-limiting examples.

VI. Examples:

[00157] The invention is illustrated in the following non-limiting examples.

Example 1 : in vitro screening of solid dispersions of compound (1 -1 )

[00158] Ten solid dispersions were prepared using compound (1 -1) and one of five polymers, including hypromellose acetate succinate (HPMCAS-M), hypromellose phthalate (HPMCP-HP55), polyvinylpyrrolidone (PVP), PVP -vinyl acetate (PVP-VA), and Euragit LI 00-55, at both 25% and 50% of compound (1 -1 ) loading, for each polymer. Solid dispersions were prepared by a solvent evaporation method, using spray-drying followed by secondary drying in a low-temperature convection oven. The performance of each solid dispersion was assessed via a non-sink dissolution performance test which measured both the total amount of drug and the amount of free drug present in solution over time. Non-sink dissolution was chosen because it best represents the in vivo situation for low soluble compounds. This test included a "gastric transfer" of dispersion from gastric H (0.1N NaCl, pH 1.0) to intestinal pH (FaFSSIF, pH 6.5) approximately 30 to 40 minutes after the introduction of dispersion to the test medium, simulating in vivo conditions. [FaFSSIF is Fasted State Simulated Intestinal Fluid, comprised of 3 mM sodium taurocholate, 0.75 mM lechithin, 0.174 g NaOH pellets, 1.977 g NaH ₂ P0 ₄ *H ₂ 0, 3.093 g NaCl, and purified water qs 500 mL.] The amount of dissolved drug was quantified using a high-performance liquid

chromatrography (HPLC) method and an Agilent 1 100 series HPLC. The dissolution profiles of the formulations (Figures 1A-1J) showed large increases in drug solubility in all dispersion candidates relative to the unformulated compound in the same media. Of the solid dispersions, the 25% compound (1-1) in PVP, 25% compound (1-1) in HPMCAS-M, and 50% compound (1 -1) in HPMCAS-M dispersions were the most promising candidates for enhanced oral absorption as compared to the unformulated compound, based on finding higher levels of free drug released at intestinal pH.

Example 2: in vivo screening of solid dispersions of compound (1-1)

[00159] The three most promising solid dispersions of compound (1-1), namely the 25% compound (1-1) in PVP, 25% compound (1-1) in HPMCAS-MG, and 50% compound (1 -1) in HPMCAS-M dispersions, were prepared at larger scale for in vivo studies. Each formulation was assessed in the in vitro dissolution test described in Example 1. To ensure that these dispersions were both amorphous and homogeneous, each dispersion was assessed by powder x-ray diffraction (PXRD) and modulated differential scanning calorimetry (mDSC). Additionally, to understand the effect of water on the glass transition temperature (Tg) for each dispersion, mDSC was performed on samples first equilibrated at a set relative humidity (i.e., 25%, 50%, and 75% RH) for at least 18 hours. [Water can act as a plasticizer for solid dispersions and the hygroscopicity of the system due to the active compound or polymer can affect the amount of water uptake by these systems.]

[00160] The non-sink dissolution results (Figures 2A-2C) were comparable to those found for the dispersions in Example 1. PXRD results (Figure 3) showed no evidence of crystalline compound in any of the dispersions and mDSC results (Figures 4A-4C) showed a single glass transition temperature (Tg) for each dispersion, indicating that each dispersion was homogeneous. The x-ray diffractomer was a Bruker D-2 Phaser. An inverse relationship between Tg and relative humidity was observed for each (Figure 5). Notably, for the 25% compound (1-1) in PVP solid dispersion equilibrated at 75% RH, there appeared to be two Tgs, indicating that phase separation was occurring, and this dispersion also showed a melt event at 75% RH, suggesting that crystallization occurred during the RH equilibration (Figure 6). This finding suggests that the 25% compound (1- 1) in PVP dispersion may be less stable than the HPMCAS-M dispersions.

[00161] To assess the bioavailability of the three dispersions, groups of male beagle dogs (three per group) were given a 3 mg/kg dose of an aqueous suspension of solid dispersion of compound (1- 1) administered by oral gavage or a 1 mg/kg dose of compound (1-1) dissolved in

water: ethanokpolyethylene glycol (PEG) 400 (60:20:20) and administered as an intravenous bolus into the cephalic vein. Blood samples were collected from the jugular vein of each animal at 0 (pre- dose), 5, 15, and 30 minutes and 1, 2, 4, 8, 12, and 24 hours following intravenous administration and at 0 (pre-dose), 15 and 30 minutes and 1, 2, 4, 8, 12, and 24 hours following oral gavage administration. The amount of compound (1-1) present in each sample was detected using a qualified LC-MS/MS method with a lower limit of quantification of 0.5 ng/mL. The area under the plasma concentration-time curve (AUC) was determined by use of the linear trapezoidal rule up to the last measurable concentration without extrapolation of the terminal elimination phase to infinity. The elimination half-life (ti/ ₂ ) was calculated by least-squares regression analysis of the terminal linear part of the log concentration-ime curve. The maximum plasma concentration (C _max ) and the time to C _m a _x (t _m a _x ) were derived directly from the plasma concentration data. The oral

bioavailability (F) was calculated by dividing the dose normalized AUC after oral administration by the dose normalized AUC after intravenous administration and reported as percentages (%).

Results, summarized in Table 1 below, gave mean oral bioavailabilities of the 25% compound (1-1) in PVP, 25% compound (1-1) in HPMCAS-M, and 50% compound (1 -1) in HPMCAS-M solid dispersions of 58%, 49%, and 74%, respectively.

Table 1 : pharmacokinetic parameters of compound (1-1) after oral (po) and intravenous (iv) administrations to dogs (the values are averages from three dogs)

AUC: area under the plasma concentration-time curve; C _max : maximum plasma concentration; F: bioavailability; HPMCAS: hypromellose acetate sodium; IV: intravenous; PEG: polyethylene glycon; PO; per os, oral; PVP: polyvinylpyrrolidone; t _max : time of C _max ; n'- plasma elimination half-life

Example 3: preparation and clincial use of capsules containing a solid dispersion of compound (1-1)

[00162] A gelatin capsule of 10 mg strength was prepared for initial clinical studies in patients with hematologic malignancies. Based on results of in vitro and in vivo testing of solid dispersions of compound (1 -1), as described in Examples 1 and 2, a 50% compound (1-1) in HPMCAS-M solid dispersion was selected for capsule development. Capsule development was initiated targeting a fill weight of 190 mg in a size 3 hard gelatin capsule, as this configuration would potentially allow increasing the capsule strength by filling a larger size capsule while maintaining the pharmaceutical composition. Based on experience, four capsule formulations were designed with different amounts of disintegrant and with and without wetting agent. Since all four formulations showed similar disintegration test and dissolution test results, the simplest formulation (without wetting agent and minimum disintegrant) was selected for manufacturing. Manufacturing process development and scale-up studies were performed to confirm the spray drying process and post-drying times for the solid dispersion; blending parameters; roller compaction and milling of the blend to achieve target bulk density of approximately 0.60 g/cc; and capsule filling conditions.

[00163] Crystalline compound (1-1) and the polymer hypromellose actate succinate (HPMCAS- M) were dissolved in acetone and spray-dried to produce solid dispersion intermediate (SDI) granules containing a 50% compound (1 -1) loading. The SDI was shown by PXRD analysis to be amorphous and by mDSC analysis to be homogeneous (i.e., single Tg under ambient conditions). The 50% compound (1-1) in HPMCAS-M solid dispersion (1000 g) and excipients, including micro crystalline cellulose filler-binder (4428 g), croscarmellose sodium disintegrant (636 g), colloidal silicon dioxide dispersant/lubricant 156 g), magnesium stearate dispersant/lubricant (156 g), and lactose monohydrate filler (5364 g) were blended in stages in a V-blender. The blend was them compacted and granulated to obtain a bulk density of approximately 0.6 g/mL. The blend was dispensed into size 3 hard gelatin capsules (target fill weight: 190 mg) using an automated filling machine and finished capsules were polished using a capsule polisher machine.

[00164] Pharmacokinetic assessments were performed following oral dosing of 10 mg capsules containing the 50% compound (1-1) in HPMCAS solid dispersion and results were compared with pharmacokinetic assessments performed following oral dosing of administration of 4 x 10 mg capsules containing the Eudragit solid dispersion of compound (1-1) to healthy volunteers [00165] A comparison of the two pharmaceutical compositions is provided in Tables 2A and 2B below. The Eudragit formulation previously was described in Example 5 in US Patent Application 2009/0012064 Al , published January 8, 2009. That application noted that the Eudragit solid dispersion formulation was made by dissolving and/or dispersing the thienotriazolodiazepine of formula (A) and coating excipients, including ammonio methacrylate copolymer type B (Eudragit RS), methacrylic acid copolymer type C (Eudragit L100-55), talc, and magnesium aluminosilicate, in a mixture of water and ethanol. This heterogeneous mixture then was applied to microcrystalline cellulose spheres (Nonpareil 101 , Freund) using a centrifugal fluidizing bed granulator to produce granules that were dispensed into size 2 hydroxypropyl methylcellulose capsules.

[00166] In both clinical studies, blood levels of compound (1 -1) were determined using validated LC-MS/MS methods and pharmacokinetic analyses were performed based on plasma concentrations of compound (1 -1 ) measured at various time points over 24 hours after capsule administration. Results, summarized in Table 3 below, showed that the HPMCAS-M solid dispersion formulation had over 3 -fold higher bioavailability in humans than the Eudragit solid dispersion formulation based on AUCs (924*4 / 1 140, adjusting for difference in doses administered). Additionally, based on the observed Tmax, the HPMCAS formulation is more rapidly absorbed than the Eudragit formulation (T _max of 1 h vs 4-6 h). The marked improvement in systemic exposure with the

HPMCAS-M solid dispersion formulation is unexpected.

Table 2A: solid dispersion capsules of compound (1 -1 ) for clinical use

pharmaceutical composition containing 50% HPMCAS solid dispersion of compound (1 -1):

10 mg strength, size 3 hard gelatin capsule

Table 2B: pharmaceutical composition containing Eudragit L100-55solid dispersion of compound (1-1): 10 mg strength, size 2 hard gelatin capsule

* as anhydrate

Table 3: pharmacokinetic parameters following oral administration of solid dispersions of compound (1 -1) to humans

AUCo-24h: area under the OTX015 plasma concentration vs. time curve over 24 hours

C _max : maximum concentration in plasma

hr: hour

HPMCAS: hypromellose acetate succinate

mL: milliliter

ng: nanogram

PO: per os, oral

T _max : time of C _max

[00167] Example 4. Oral exposure in the rat

[00168] The oral bioavailability of three formulations of solid dispersions of compound (1 -1) was determined in rats. The three dispersions chosen were the 25% dispersion of compound (1-1) in PVP, the 25% dispersion of compound (1-1) in HPMCAS -MG, and the 50% dispersion of compound (1-1) in HPMCAS-MG. The animals used in the study were Specific Pathogen Free (SPF) Hsd:Sprague Dawley rats obtained from the Central Animal Laboratory at the University of Turku, Finland. The rats were originally purchased from Harlan, The Netherlands. The rats were female and were ten weeks of age, and 12 rats were used in the study. The animals were housed in polycarbonate Makrolon II cages (three animals per cage), the animal room temperature was 21 +/- 3 °C, the animal room relative humidity was 55 +/- 15%, and the animal room lighting was artificial and was cycled for 12 hour light and dark periods (with the dark period between 18:00 and 06:00 hours). Aspen chips (Tapvei Oy, Estonia) were used for bedding, and bedding was changed at least once per week. Food and water was provided prior to dosing the animals but was removed during the first two hours after dosing.

[00169] The oral dosing solutions containing the 25% dispersion of compound (1-1) in PVP, the 25% dispersion of compound (1-1) in HPMCAS-MG, and the 50% dispersion of compound (1 -1) in HPMCAS-MG were prepared by adding a pre-calculated amount of sterile water for injection to containers holding the dispersion using appropriate quantities to obtain a concentration of 0.75 mg/mL of compound (1-1). The oral dosing solutions were subjected to vortex mixing for 20 seconds prior to each dose. The dosing solution for intravenous administration contained 0.25 mg/mL of compound (1-1) and was prepared by dissolving 5 mg of compound (1-1) in a mixture containing 4 mL of polyethylene glycol with an average molecular weight of 400 Da (PEG400), 4 mL of ethanol (96% purity), and 12 mL of sterile water for injection. The dosing solution containing the 25% dispersion of compound (1-1) in PVP was used within 30 minutes after the addition of water. The dosing solutions containing the 25% dispersion of compound (1 -1) in

HPMCAS-MG and the 50% dispersion of compound (1-1) in HPMCAS-MG were used within 60 minutes of after the addition of water. A dosing volume of 4 mL/kg was used to give dose levels of compound (1-1) of 1 mg/kg for intravenous administration and 3 mg/kg for oral administration. The dosing scheme is given in Table 4.

[00170] Table 4. Dosing scheme for rat oral exposure study.

6 219.2 0.88 25% dispersion of compound (1 -1 ) oral

in PVP

7 251.6 1 .01 25% dispersion of compound (1 -1 ) oral

in HPMCAS-MG

8 240.4 0.96 25% dispersion of compound (1 -1 ) oral

in HPMCAS-MG

9 238 0.95 25% dispersion of compound (1 -1 ) oral

in HPMCAS-MG

10 226.6 0.91 50% dispersion of compound (1 -1 ) oral

in HPMCAS-MG

1 1 228.4 0.91 50% dispersion of compound (1 -1 ) oral

in HPMCAS-MG

12 228.5 0.91 50% dispersion of compound (1 -1 ) oral

in HPMCAS-MG

[00171] Blood samples of approximately 50 μΐ _^ were collected into Eppendorf tubes containing 5 μL of ethylenediaminetetraacetic acid (EDTA) solution at time points of 0.25, 0.5, 1 , 2, 4, 8, 12, and 24 hours after dosing, with each sample collected within a window of 5 minutes from the prescribed time point. From each sample, 20 μL· of plasma was obtained and stored at dry ice temperatures for analysis. Analysis of each sample for the concentration of compound (1 -1) was performed using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantitation of 0.5 ng/mL.

[00172] Pharmacokinetic parameters were calculated with the Phoenix WinNonlin software package (version 6.2.1 , Pharsight Corp., CA, USA) with standard noncompartmental methods. The elimination phase half-life (ti/ ₂ ) was calculated by least-squares regression analysis of the terminal linear part of the log concentration-time curve. The area under the plasma concentration-time curve (AUC) was determined by use of the linear trapezoidal rule up to the last measurable concentration and thereafter by extrapolation of the terminal elimination phase to infinity. The mean residence time (MRT), representing the average amount of time a compound remains in a compartment or system, was calculated by extrapolating the drug concentration profile to infinity. The maximum plasma concentration (Cma _X ) and the time to Cma _X (t _max ) were derived directly from the plasma concentration data. The tentative oral bioavailability (F) was calculated by dividing the dose normalised AUC after oral administration by the dose normalised AUC after intravenous administration, i.e. F = (AUC(oral)/Dose(oral))/(AUC(intravenous) / Dose(intravenous))] and is reported as percentage (%). [00173] The pharmacokinetic parameters are given in Table 5, and the plasma concentration versus time plots are shown in Figures 7 and 8.

Table 5. Pharmacokinetic parameters of compound (1-1) after oral and intravenous administrations. The values are an average from three animals.

[00174] Example 5. Preparation of spray dried dispersions.

[00175] Spray dried dispersions of compound (1 -1 ) were prepared using five selected polymers: HPMCAS-MG (Shin Etsu Chemical Co., Ltd.), HPMCP-HP55 (Shin Etsu Chemical Co., Ltd.), PVP (ISP, a division of Ashland, Inc.), PVP-VA (BASF Corp.), and Eudragit LI 00-55 (Evonik Industries AG). All spray dried solutions were prepared at 25% and 50% by weight with each polymer. All solutions were prepared in acetone, with the exception of the PVP solutions, which were prepared in ethanol. For each solution, 1.0 g of solids (polymer and compound (1-1)) were prepared in 10 g of solvent. The solutions were spray dried using a Buchi B-290, PE-024 spray dryer with a 1.5 mm nozzle and a Buchi B-295, P-002 condenser. The spray dryer nozzle pressure was set to 80 psi, the target outlet temperature was set to 40 °C, the chiller temperature was set to -20 °C, the pump speed was set to 100%, and the aspirator setting was 100%. After spray drying, the solid dispersions were collected and dried overnight in a low temperature convection oven to remove residual solvents.

[00176] Example 6: Stability with humidity and temperature.

[00177] Table 6

[00178] Spray dried dispersions of compound (1 -1 ) in HPMCAS-MG were assessed for stability by exposure to moisture at elevated temperature. The glass transition temperature (Tg) as a function of relative humidity was determined at 75% relative humidity, 40 °C for 1 , 2 and 3 months. The spray dried dispersion was stored in an LDPE bag inside a HDPE bottle to simulate bulk product packaging. The data is summarized in Table 6. At time zero, the Tg was 134 °C, at 1 month the Tg was 134 °C, at 2 months the Tg was 135 °C and at 3 months the Tg was 134 °C and only a single inflection point was observed for each measurement. X-ray diffraction patterns were also obtained for each sample. Figure 9 illustrates a powder X-ray diffraction profile of solid dispersions of compound (1-1) in HPMCAS-MG at time zero of a stability test. Figures 10, 11 and 12 illustrate powder X-ray diffraction profiles of solid dispersions of compound (1 -1 ) in HPMCAS-MG after 1 month, 2 months and 3 months, respectively, after exposure at 40 °C and 75 % relative humidity.

[00179] The patterns did not show any diffraction lines associated with compound (1-1).

[00180] Example 7: Cell lines and selection of primary cells

[00181] Different representative cell lines for ALL including Jurkat cells T-ALL), RS 4-1 1 (MLL-AF4 B-precursor ALL), TO M-1, BV173 (both Ph+ ALL) and AML including K562 (Ph+ CML in blast crisis,), HL-60 (NRAS driven AML2), NOMOl (MLL-AF9 driven AML), KG1 (BMP-FGRF+ AML6) and its more immature subtype KG la were cultured in RPMI 1640 (Gibco Invitrogen, Basel, Switzerland) supplemented with 10% or 20% heat-inactivated fetal calf serum respectively, 2 mM L-glutamine, 100 IU/mL penicillin, and 100 g/mL streptomycin.

[00182] Mononuclear cells (MNC) from the bone marrow (BM) were isolated by Ficoll-Paque PLUS density gradient (Amersham Biosciences, Sunnyvale, USA). Patient cells were maintained in IMDM (Gibco) supplemented with 10% heat- inactivated fetal calf serum, 2 mM L-glutamine, 100 IU/mL penicillin, and 100 g/mL streptomycin without growth factors.

[00183] Example 8: MTT- assay, apoptosis assessment and cell cycle analysis [00184] MTT-assay: cells were seeded first into 24-well plates at the density of 106 per well to avoid variations of concentrations in smaller volumes and treated with different doses of OTX015 prepared freshly from ImM stock solution in DMSO. Cells were transferred to 96-well plates for MTT-assay. Untreated cells and cells treated with equal amounts of DMSO (0.2-1%) used for dilution of OTX015 were used as controls. The 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) (Molecular Probes, Eugene, USA) was prepared as a stock of 5 mg/ml in PBS. 0.5 mg/mL of MTT solution was then added per well and incubated in the dark at 37°C for 4h. Cells were then lysed with 25% SDS lysis buffer and absorbance was read at 570 nm. Two independent experiments were run for each cell line. GI50 values were calculated with Prism v5 software (GraphPad Inc., La Jo 11a, USA).

[00185] Apoptosis assessment: a total of lxl 0 ⁶ cells derived from patients or cell lines were resuspended in 1 mL culture medium and incubated with the indicated dosages of OTX015 prepared freshly from ImM stock solution in DMSO. Control cells were incubated with the corresponding amount of dimethyl sulfoxide (DMSO 0.2-1 %) to exclude toxicity of the excipient. Apoptotic cells were detected by cytofiuorometric analysis using a FACScan (Becton Dickinson, Mountain View, USA). Cells were stained with propidium iodide (PI; 5 μg/mL; Becton Dickinson) and

concomitantly for 15 minutes at RT with annexin-V-FITC (Becton Dickinson) according to the manufacturer's instructions to determine outer membrane phosphatidyl serine exposure. Data were analyzed with the Flowjo (Tree Star Inc., Ashland, USA) flow cytometry software.

[00186] Cell cycle analysis: For conventional cell-cycle analysis, lxl 0 ⁶ cells were harvested, washed in PBS, and fixed in 70% ice cold ethanol. Cells were incubated with 100 μg/mL R Ase (Sigma, Saint-Quentin Fallavier, France) and stained with PI (25 μg/mL, Becton Dickinson) followed by an incubation period of 30 minutes at 37°C. Subsequently, cell-cycle distribution was determined by cytofiuorometric analysis. Data were analyzed with the Flowjo (Tree Star Inc., Ashland, USA) flow cytometry software.

[00187] Compound (1 -1 ) induced apoptosis in three ALL cell lines (Jurkat, RS 4-1 1 , TOM-1) and four AML cell lines (HL60, K562, KG1 and KG l a) that were treated with different doses of the drug as detected by outer membrane phosphatidylserine exposure and propidium iodide

incorporation at different time points (Figures 13A-13C and Figures 14A-14D). Compound (1 -1 ) induced apoptosis in all cell lines tested but to a lesser extent in K562 and KG la cells (Figure 14 B, D). In all other cell lines, 50% of cells became apoptotic within 12 to 24 hours after treatment with 100 nM of Compound (1 -1 ).

[00188] Furthermore, Compound (1 -1) induced cell cycle arrest in all cell lines (Figures 15A- 15C). The apoptosis data showed that K562, KGla and TOM-1 were less sensitive to cell cycle degradation after exposure to Compound (1 -1 ). Of note, lower doses of Formula 2 (10 nM) induced apoptosis after prolonged incubation, i.e. 72 hours (as tested in KG1 cells and shown in Figure 16).

[00189] Table 7: MTT assay at 72h and GI50 values. Cell Line GI50/nM Range/nM

K562 1 1342.5 8352-14333

HL60 1306.7 543-2298

KG1 198.3 168.5-213.6

KGla 1342.9 453.7-2214

NOMOl 229.1 96.94-332.7

Jurkat 249.7 161.5-346.6

RS4-1 1 34.2 29.24-38.84

BV-173 161 105.5-207.6

TOM-1 133.1 30.7-200.8

[00190] AML and ALL cell lines were exposed to increasing concentrations of compound (1-1), (0.1 nM-10 μΜ). Percent of proliferating cells were determined by MTT assay at 72h and GI50 values were calculated by Prism software from means ± SD from quintuplicates. GI50 values were expressed as means from 3 independent experiments. [00191] As shown in Table 7, compound (1-1) induced apoptosis in AML cell lines (see KGla and NOMOl) and in ALL cell lines (see RS4-11 , BV-173, Jurkat and TOM-1) in a dose-dependent manner increased when these cells were treated with different doses of compound (1-1) as detected by outer membrane phosphatidylserine exposure and propidium iodide incorporation at 72h as illustrated in Figures 39A-39C. Among AML cell lines, 2 appeared sensitive (KG1 and NOMOl) with GI50 values of 198.3 and 229.1 nM respectively. Two cell lines were less sensitive (HL60 and KGla) with GI values of 1.3 μΜ each while K562 were considered resistant with an GI50 value of 11.3 μΜ. OTX015 caused a dose-dependent decrease in cell viability in all ALL cell lines, with GI50 between 34.2-249.7 nM

[00192] Generally, the half maximal inhibitory concentration (IC-50 value) of a compound is a measure of the effectiveness of the compound in inhibiting a biological or a biochemical function. IC-50 value, therefore, can be considered a quantitative measure indicating how much of a particular drug or any chemical substance is required to inhibit a given biological process by half (50%). Sometimes, however, GI-50 is used to symbolize the value for the concentration that causes 50% growth inhibition. The use of GI-50 indicates that a correction for the cell count at time zero has been made. An example of one formula for calculating GI-50 value defines GI-50 as the concentration of test compound where 100 x (T - T ₀ )/(C - T ₀₎ = 50, wherein T is the optical density of the test well after a 48h period of exposure to test drug is T, for example; To is the optical density the test well at time zero. [00193] Furthermore, compound (1 -1 ) decreased S phase fraction in almost all cell lines (Figures 40A-40H). This effect was more pronounced in the ALL cell lines RS4-1 1 and BV-173 with accumulation in Gl in those cell lines.

[00194] Example 9: Expression of Bromodomains [00195] Expression of bromodomains was studied in different cell lines and patient samples using quantitative -real time polymerase chain reaction (QT-PCR) analysis. The total RNA obtained after extraction with a reagent solution of phenol and guanidine isothiocyanate (TRIzol® brand reagent, Invitrogen, Grand Island, NY) was titrated to 1 μg/μL and stored at -80 °C. The complementary DNA (cDNA) was synthesized from 1 μg RNA. The QT-PCR reactions were performed in a volume of 25 from a tenth of the cDNA (equivalent to 100 ng of RNA) on a thermocycler ABI 7900HT in standard mode (lcycle of 2 minutes at 50 °C-10 minutes at 95 °C followed by 50 cycles of 15 seconds at 95 °C -1 minute at 6 °C).

[00196] The different cell lines expressed BRD2, BRD3 and BRD4 at different levels as detected by QT-PCR (Figure 17A-17C). Three different forms of BRD4 were studied: the consensus form (BRLMc), an intermediate form, and a short form (BRLMs). There was no difference for the expression of the different forms among cell lines. There was no obvious correlation between apoptosis and BRD expression. The AML cell line K562 had the lowest expression level and had lower sensitivity to Compound (1 -1) treatment. There was no difference between BRD expression levels compared to the breast cancer cell line MCF-7. Very high levels of BRD were observed in selected CD34+ cells from cord blood. Expression of BRD2, BRD3 and BRD4 was studied in patient samples. Patient characteristics are summarized in Table 8. Among ALL patients, Ph+ ALL showed lower BRD expression levels while BRD expression levels among AML patients was more heterogeneous (Figure 17A-17C).

[00197] Table 8: ALL and AML patient characteristics

10 T-ALL normal CALM/ AF 10 na

1 1 A ML normal CEBPA+ 52

12 A ML normal MLL-PTD 75

13 AML normal MLL-PTD 88

14 AML norm al FLT3-TTD 90

15 AML normal FLT3-ITD 19

16 AML normal FLT3-ITD 92

17 AML normal FLT3-ITD and MLL-PTD 47

18 AML inv(16) CBFB/MYH11 40

19 AML inv(16) CBFB/MYH11 na

20 AML complex unk 93

21 AML complex unk 22

22 AML normal NPM1 + 49

23 AML normal NPM1 + 13

24 AML normal NPM1 + 20

25 AML normal NPM1 + 90

26 AML normal NPM1 + 24

27 AML normal NPMl+ and FLT3-ITD 94

28 AML t(8;21) AML1/ETO 89

29 AML t(8;21) AML1/ETO 49

[00198] Treatment with Compound (1-1) was studied to determine if it induces down-regulation of BRD2, BRD3, BRD4 and c-MYC. The oncogene c-MYC is a downstream partner of BRD4 for leukemia maintenance (Delmore, J. E, et al. Cell. 2011 ; 146:904-917). Other small inhibitors such as JQ1 induce BRD4 down-regulation and subsequently c-MYC down-regulation. Different leukemia cell lines were treated with 100 nM Formula 2 and observed rapid down-regulation of BRD2, BRD3 and BRD4 associated with c-MYC down-regulation within 3 hours at the protein level (Figures 18A and 18B). In KG1 and KGla protein down-regulation was not associated with cDNA decrease (Figures 18A and 18B) compared to TOM-1 cells (Figures 19A-19D) within 3 hours. In Jurkat and RS 4-11 cells, cDNA for BRD 2-4 was initially down-regulated but increased before 3 hours (Figure 19A-19D). The results show that Formula 2 induces rapid down-regulation of BRD2, BRD3, BRD4 and c-MYC.

[00199] Further as illustrated in Figures 41A- 41H, the different cell lines expressed BRD2, BRD3 and BRD4 at heterogenous levels as detected by RQ-PCR with bcr-abl driven cell lines BV- 173 and K562 having the lowest gene expression levels (Figures 41 A-41B). There was no obvious correlation between biologic effects including MTT, apoptosis or cell cycle arrest and BRD gene expression. We investigated modulation of BRD4, BRD2 and BRD3 at the cDNA level by OTX015 treatment with 250 nM and 500 nM respectively at 48h. We were not able to detect a consistent down regulation of BRD4, BRD2 or BRD3 (Figure 41C-41H) by Compound (1 -1) treatment while a significant upregulation of BRD3 and BRD2 in KG1, K562 and Jurkat and increase of BRD2 in KG1 and HL60 are detected.

[00200] Example 10: Efficacy of Compound (1-1) to induce apoptosis in CD34 ⁺ and CD34 ^" cells

[00201] The efficacy of Compound (1-1) to induce apoptosis in primary cells was investigated. CD34+ and CD34- cells were obtained by positive selection with CD34+ microbeads from cord blood (healthy controls) and one AML patient. Routine immunophenotyping showed that 30% of blast cells were positive for CD34+. Treatment of CD34+ and CD34- cord blood cells demonstrated toxicity for immature CD34+ cells at the 500 nM dose level while the mature compartment remained unaffected (Figure 20). Treatment of CD34 ⁺ and CD34 ^" AML cells showed in vitro induction of apoptosis in a dose dependent manner.

[00202] Apoptosis patterns for CD34 ^" at 24 hours at different concentrations of Compound (1 -1 ) are illustrated in Figures 32A-32C.

[00203] Example 11 : Apoptosis after short exposure to Compound (1 -1 )

[00204] Figures 21A-21T show apoptosis at 96 hours after short exposure to Compound (1-1). HL60, KS62, Jurkat, and RS4-11 cells were treated with 10 nM and 100 nM of Compound (1-1) , respectively. Cells were washed at 6 hours (10 nM and 100 nM) and 24 hours (10 nM), supernatant was discarded and cells seeded again in fresh medium. Apoptotic cells were assessed by FACS analysis at 96 hours (24 to 72 hours not shown) and defined as Annexin V+ with or without PI uptake. One representative experiment of two is shown in Figures 21 A-2 IT. [00205] Example 12: Apoptosis after exposure to various concentrations of Compound (1-1)

[00206] Figures 22A-22L illustrate flow cytometric analysis of apoptosis data in the AML cell line HL60 when exposed to 0 nM, 1 nM and ΙΟηΜ of Compound (1 -1). Figures 23A, 23B and 23C illustrate apoptosis for HL60 cell lines of Figures 22A-22L.

[00207] Treatment with Compound (1-1) induced significant apoptosis in HL60 and K562 cells (Figures 24A and 24B, respectively). Significant apoptosis was also observed in KG1 and KGla cells (Figures 25 A and 25B), Jurkat and RS4-11 cells (Figures 26A and 26B), and TOM1 cells (Figure 27). K562 was less sensitive to treatment with Compound (1-1), with 20% apoptopic cells observed at 24 hours. Prolonged exposure at 1 and 10 nM concentrations yielded different response patterns: after an exposure of 96 hours at 10 nM only, HL60, KG1 and Jurkat cells displayed >90% and TOM-1 70% apoptosis; in contrast, KGla, MLL-fusion RS4-11 and K562 cells displayed lower apoptosis (45%, 30% and 20%, respectively), while apoptosis was observed at levels of 15% to 20% in controls. [00208] Example 13: Apoptosis following drug washout

[00209] Drug washout after a shorter exposure of 6 hours was also associated with significant delayed apoptosis at 96 hours in the sensitive HL60 and Jurkat lines (Figures 28 and 29A, 29B, respectively), but not in the less sensitive K562 and RS4-11 cell lines (Figures 30A and 30B).

[00210] MTT assay data in three ALL cell lines are shown in Figure 31 A and 3 IB. [00211] Example 14: Apoptosis in blood and marrow

[00212] Figures 33A-33G and 34A-34B illustrate the apoptosis for various concentrations of Compound (1-1) for blood and marrow cells.

[00213] Example 15: c-MYC kinetics

[00214] c-MYC kinetics in AML and ALL cell lines were measured upon treatment with Compound (1-1) and are shown in Figure 35. BRD4 kinetics in AML and ALL cell lines were also measured upon treatment with Compound (1-1) and are shown in Figure 36. Figure 37 illustrates BRD2 kinetics in AML and ALL cell lines upon treatment with Compound (1 -1) . Figure 38 illustrates BRD3 kinetics in AML and ALL cell lines upon treatment with Compound (1-1).

[00215] The oncogene c-MYC is thought to be activated by BRD4 and is crucial for leukemia maintenance. Other small BRD inhibitors (i.e. JQ1) induced BRD4 downregulation and

subsequently c-MYC downregulation in different settings. We determined basal gene expression levels of c-MYC in different leukemia cell lines showing heterogeneous results without clear correlation to biologic effects of Compound (1-1) in regard to MTT, apoptosis or cell cycle effects (Figure 42A and 42B). Those cell lines were treated with 250 nM and 500 nM of Compound (1-1) and c-MYC downregulation was observed in all cell lines as detected by QT-PCR at 48h (Figure 42C and 42D). [00216] Due to the absence of clear correlations of BRDs and c-MYC basal gene expression and modulation by Compound (1 -1 ) detected by RQ-PCR we next investigated potential effects of Compound (1-1) at the protein level for BRD 4, BRD2 and BRD 3 as well as c-MYC.

[00217] In the selected AML cell line HL60 BRD4 and BRD3 remained unaffected after 72h Compound (1-1) exposure at 500 nM with a transient downregulation of c-MYC observed after 24h-treatment (Figure 43A-43C) while the almost resistant AML cell line K562 displayed downregulation of BRD4, BRD3 and c-MYC starting after 24h exposure (Figure 43D-43F). For the sensitive ALL cell lines, Jurkat displayed c-MYC downregulation at 48h and 72h (Figure 43G-43I) while BRD4, BRD3 and c-MYC remained unaffected in RS4-11 (Figure 43J-43L). [00218] Example 16: Immunoblots

[00219] Protein extracts were prepared from 7xl0 ⁶ cells; 30 μg were separated on sodium dodecyl sulfate (SDS)-polyacrylamide gels using 4-15% gradient gels (Bio-Rad, Marnes-la-Coquette, France) and transferred to nitrocellulose membranes using Mini Trans-Blot Electrophoretic Transfer cell (Bio-Rad).The membranes were blocked with LiCor blocking buffer (LiCor, Lincoln, NE, USA) and incubated with the respective primary antibody: anti-BRD4 (Epitomics 5716-1, Burlingame, USA), anti-BRD3 (ab56342, AbCam, UK), anti-BRD2 (ab37633, AbCam, UK), anti c-MYC (sc- 764 (N262), Santa Cruz, USA) and anti-GAPDH (Invitrogen 398600, Grand Island, USA). Blots were stained with either goat anti-rabbit InfraRedDye 680RD or goat anti-mouse InfraRedDye 800CWsecondary antibody (LiCor). Membranes were imaged using a LiCor Odyssey scanner. Boxes were manually placed around each band of interest, which returned near-infrared fluorescent values of raw intensity with intra-lane background subtracted using Odyssey 3.0 analytical software (LiCor).

[00220] Blots for BRD2 were stained with either goat (BRD2) anti-rabbit peroxidase-labeled or goat anti-mouse (GAPDH) peroxidase-labeled secondary antibody (Biorad, Hercules, USA) and were revealed using an enhanced chemiluminescence detection system (ECL and ECL plus, GE Healthcare, Buckinghamshire, UK).

[00221] Example 17: Quantitative-real time polymerase chain reaction (RQ-PCR)

[00222] The total R A obtained after extraction with TRIZOL (Invitrogen, Grand Island, USA) were titrated to 1 μg/uL and stored at -80°C. The complementary DNA (cDNA) was synthesized from 1 μg RNA. The RQ-PCR reactions (BRD2, BRD3, BRD4, c-MYC and ABL) were performed in a volume of 25 μΐ from a tenth of the cDNA (equivalent to lOOng of RNA) on a thermocycler ABI7900HT in standard mode (Icycle of 2 minutes at 50°C-10 minutes at 95°C followed by 50 cycles of 15 seconds at 95°C -1 minute at 60°C). The primers used are summarized in Table 9.

[00223] Table 9 : Primers used for PCR.

[00224] Example 18: Effects of Compound (1 -1) in primary cells

[00225] We further studied effects of Compound (1 -1) on primary patient cells. We treated ex vivo 5 samples from AML patients and 2 ALL including 1 ALL Ph+ patient. Patient characteristics are shown in Figure 44D. Compound (1 -1 ) induced apoptosis in primary AML patient samples at various degrees ranging from 35-85% (Figures 44A-44C). The Ph+ ALL patient appeared to be resistant. [00226] Basal gene expression of BRD2, BRD3 and BRD4 in patient samples was assessed by RQ-PCR analysis. Patient characteristics are summarized in Table 10. Among ALL patients, Ph+ ALL showed lower BRD expression levels (Figures 47A and 47B; Patients 3 to 6) while BRD expression levels among AML patients were more heterogeneous (Figures 47C and 47D). 227] Table 10: Characteristics of different ALL and AML patients studied for BRD expression.

Molecular

N° Gender Disease Karyotype

Biology

1 M B-ALL Normal -

2 F B-ALL Normal -

3 M B-ALL PH1+ bcr/abl

4 F B-ALL PH1+ bcr/abl

5 M B-ALL PH1+ bcr/abl

6 M B-ALL PH1+ bcr/abl

7 M T-ALL UK -

8 F T-ALL UK -

9 M T-ALL UK -

10 M T-ALL Normal CalmAfl O

CEBP

1 M AML Normal alpha

2 M AML Normal dup MLL

3 F AML Normal dup MLL

4 F AML Normal FLT3 ITD

5 M AML Normal FLT3 ITD

6 F AML Normal FLT3 ITD

FLT3 ITD

+ Dup

7 M AML Normal MLL

CBF

8 M AML inv 16 MYH

CBF

9 M AML inv 16 MYH

10 F AML Complex -

1 1 M AML Complex -

12 F AML Normal NPM1

13 M AML Normal NPM1

14 F AML Normal NPM1

15 M AML Normal NPM1

16 M AML Normal NPM1

NPM1 +

17 F AML Normal FLT3 ITD

18 M AML t(8;21) AML ETO

19 M AML t(8;21) AML ETO [00228] Protein extracts could be obtained from BM cells of patient 5 (Table 10; Figure 44) upon ex vivo treatment with 250 and 500 nM of OTX015 respectively. Those cells displayed

downregulation of c-MYC after 72h exposure to OTX015 (45A-45C).

[00229] It will be appreciated by those skilled in the art that changes could be made to the exemplary embodiments shown and described above without departing from the broad inventive concept thereof. It is understood, therefore, that this invention is not limited to the exemplary embodiments shown and described, but it is intended to cover modifications within the spirit and scope of the present invention as defined by the claims. For example, specific features of the exemplary embodiments may or may not be part of the claimed invention and features of the disclosed embodiments may be combined. Unless specifically set forth herein, the terms "a", "an" and "the" are not limited to one element but instead should be read as meaning "at least one".

[00230] It is to be understood that at least some of the figures and descriptions of the invention have been simplified to focus on elements that are relevant for a clear understanding of the invention, while eliminating, for purposes of clarity, other elements that those of ordinary skill in the art will appreciate may also comprise a portion of the invention. However, because such elements are well known in the art, and because they do not necessarily facilitate a better understanding of the invention, a description of such elements is not provided herein.

[00231] Further, to the extent that the method does not rely on the particular order of steps set forth herein, the particular order of the steps should not be construed as limitation on the claims. The claims directed to the method of the present invention should not be limited to the performance of their steps in the order written, and one skilled in the art can readily appreciate that the steps may be varied and still remain within the spirit and scope of the present invention.